

(19) World Intellectual Property
Organization
International Bureau



(43) International Publication Date
21 May 2004 (21.05.2004)

PCT

(10) International Publication Number
WO 2004/041210 A2

- (51) International Patent Classification⁷: **A61K** 19426 (US). SEEFELD, Mark, Antony [US/US]; 1250 South Collegeville Road, Collegeville, PA 19426 (US).
- (21) International Application Number: PCT/US2003/035206 (74) Agents: MADDEN, Laura, K. et al.; Smithkline Beecham Corporation, Corporate Intellectual Property, UW 2220, 709 Swedeland Road, P.O. Box 1539, King of Prussia, PA 19406-0939 (US).
- (22) International Filing Date: 4 November 2003 (04.11.2003)
- (25) Filing Language: English (81) Designated States (*national*): AE, AG, AL, AU, BA, BB, BR, BZ, CA, CN, CO, CR, CU, DM, DZ, EC, EG, GD, GE, HR, HU, ID, IL, IN, IS, JP, KP, KR, LC, LK, LR, LT, LV, MA, MG, MK, MN, MX, NO, NZ, OM, PH, PL, RO, SC, SG, TN, TT, UA, US, UZ, VN, YU, ZA.
- (26) Publication Language: English
- (30) Priority Data: 60/423,872 5 November 2002 (05.11.2002) US (84) Designated States (*regional*): ARIPO patent (BW, GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW), Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European patent (AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO, SE, SI, SK, TR), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG).
- (71) Applicant (*for all designated States except US*): SMITHKLINE BEECHAM CORPORATION [US/US]; One Franklin Plaza, P.O. Box 7929, Philadelphia, PA 19101 (US).
- (72) Inventors; and
- (75) Inventors/Applicants (*for US only*): AXTEN, Jeffrey, Michael [US/US]; 1250 South Collegeville Road, Collegeville, PA 19426 (US). GALLAGHER, Timothy, Francis [US/US]; 1250 South Collegeville Road, Collegeville, PA 19426 (US). MILLER, William, Henry [US/US]; 1250 South Collegeville Road, Collegeville, PA
- Published:**
— *without international search report and to be republished upon receipt of that report*
- For two-letter codes and other abbreviations, refer to the "Guidance Notes on Codes and Abbreviations" appearing at the beginning of each regular issue of the PCT Gazette.*



WO 2004/041210 A2

(54) Title: ANTIBACTERIAL AGENTS

(57) Abstract: Quinoline and naphthyridine derivatives useful in the treatment of bacterial infections in mammals, particularly humans.

ANTIBACTERIAL AGENTS

FIELD OF THE INVENTION

This invention relates to novel compounds, compositions containing them
5 and their use as antibacterials.

BACKGROUND OF THE INVENTION

The emergence of pathogens resistant to known antibiotic therapy is becoming a serious global healthcare problem (Chu, et al., (1996) *J. Med. Chem.*,
10 39: 3853-3874). Thus, there is a need to discover new broad spectrum antibiotics useful in combating multidrug-resistant organisms. Importantly, it has now been discovered that certain compounds have antibacterial activity, and, therefore, may be useful for the treatment of bacterial infections in mammals, particularly in humans.


15 WO99/37635, WO00/21948, WO00/21952, WO00/43383, WO00/78748, WO01/07433, WO01/07432, WO01/25227, WO0208224, WO0224684, PCT/GB01/05653, PCT/GB01/05661 and WO02040474 disclose quinoline and naphthyridine derivatives having antibacterial activity.

20 SUMMARY OF THE INVENTION

This invention comprises compounds of the formula (I), as described hereinafter, which are useful in the treatment of bacterial infections. This invention is also a pharmaceutical composition comprising a compound according to formula (I) and a pharmaceutically acceptable carrier. This invention is also a method of
25 treating bacterial infections in mammals, particularly in humans.

DETAILED DESCRIPTION OF THE INVENTION

This invention provides a compound of formula (I) or a pharmaceutically acceptable derivative thereof:



wherein:

one of Z_1 , Z_2 , Z_3 , Z_4 and Z_5 is N, one is CR^{1a} and the remainder are CH, or
 one or two of Z_1 , Z_2 , Z_3 , Z_4 and Z_5 are independently CR^{1a} and the remainder are
 5 CH;

R^1 and R^{1a} are independently hydrogen; hydroxy; (C_{1-6}) alkoxy unsubstituted or
 substituted by (C_{1-6}) alkoxy, amino, piperidyl, guanidino or amidino any of which is
 optionally N-substituted by one or two (C_{1-6}) alkyl, acyl or (C_{1-6}) alkylsulphonyl
 10 groups, $CONH_2$, hydroxy, (C_{1-6}) alkylthio, heterocyclylthio, heterocyclioxy, arylthio,
 aryloxy, acylthio, acyloxy or (C_{1-6}) alkylsulphonyloxy; (C_{1-6}) alkoxy-substituted (C_{1-6})
 alkyl; halogen; (C_{1-6}) alkyl; (C_{1-6}) alkylthio; trifluoromethyl; trifluoromethoxy; nitro;
 cyano; azido; acyl; acyloxy; acylthio; (C_{1-6}) alkylsulphonyl; (C_{1-6}) alkylsulphoxide;
 arylsulphonyl; arylsulphoxide or an amino, piperidyl, guanidino or amidino group
 15 optionally N-substituted by one or two (C_{1-6}) alkyl, acyl or (C_{1-6}) alkylsulphonyl
 groups;

provided that when Z_1 , Z_2 , Z_3 , Z_4 and Z_5 are CR^{1a} or CH, then R^1 is not
 hydrogen;

20 W_1 , W_2 , W_3 and W_4 are each independently selected from N or CR^3 ;

each R^3 is independently selected from: hydrogen; hydroxy; halogen;
 trifluoromethyl; trifluoromethoxy; cyano; nitro; azido; acyl; acyloxy; acylthio; amino,

mono- and di-(C₁₋₆)alkylamino; and substituted and unsubstituted (C₁₋₆)alkoxy, (C₁₋₆)alkyl, (C₃₋₇)cycloalkyl, aminocarbonyl, (C₁₋₆)alkylthio, (C₁₋₆)alkylsulphonyl, and (C₁₋₆)alkylsulphoxide;

5 A is (CRR)_n;

B is (CRR)_m, C=O, or SO₂;

n is 1 or 2;


m is 1 or 2

provided that when n is 1, m is 2; when n is 2, m is 1; and when B is C=O or SO₂

10 then n is 2;

each R is independently selected from: hydrogen; halogen; trifluoromethyl; trifluoromethoxy; cyano; nitro; azido; acyl; acyloxy; acylthio; amino, mono- and di-(C₁₋₆)alkylamino; and substituted and unsubstituted (C₁₋₆)alkoxy, (C₁₋₆)alkyl, (C₃₋₇)cycloalkyl, aminocarbonyl, (C₁₋₆)alkylthio, (C₁₋₆)alkylsulphonyl, and (C₁₋₆)alkylsulphoxide;

R² is a substituted or unsubstituted bicyclic carbocyclic or heterocyclic ring system of formula (A):



20

containing up to four heteroatoms in each ring in which

ring (a) is aromatic and ring (b) is aromatic or non-aromatic;

X¹ is C;

X² is N, NR⁶, O, S(O)_x, CO, CR⁴ or CR⁴R⁵;

25 X³ and X⁴ are each independently N or C;

Y¹ is a 1 to 2 atom linker group each atom of which is independently selected from N and CR⁴;

Y² is a 2 to 6 atom linker group, each atom of Y² being independently selected from N, NR⁶, O, S(O)_x, CO, CR⁴ and CR⁴R⁵;

- each R⁴ and R⁵ is independently selected from: hydrogen; (C₁₋₄)alkylthio; halo; carboxy(C₁₋₄)alkyl; halo(C₁₋₄)alkoxy; halo(C₁₋₄)alkyl; (C₁₋₄)alkyl; (C₂₋₄)alkenyl; (C₁₋₄)alkoxycarbonyl; formyl; (C₁₋₄)alkylcarbonyl; (C₂₋₄)alkenyloxycarbonyl; (C₂₋₄)alkenylcarbonyl; (C₁₋₄)alkylcarbonyloxy; (C₁₋₄)alkoxycarbonyl(C₁₋₄)alkyl; hydroxy; hydroxy(C₁₋₄)alkyl; mercapto(C₁₋₄)alkyl; (C₁₋₄)alkoxy; nitro; cyano; carboxy; amino or aminocarbonyl is optionally substituted by (C₁₋₄)alkoxycarbonyl, (C₁₋₄)alkylcarbonyl, (C₂₋₄)alkenyloxycarbonyl, (C₂₋₄)alkenylcarbonyl, (C₁₋₄)alkyl or (C₂₋₄)alkenyl and optionally further substituted by (C₁₋₄)alkyl or (C₂₋₄)alkenyl; (C₂₋₆)alkenyl; (C₁₋₄)alkylsulphonyl; (C₂₋₄)alkenylsulphonyl; or aminosulphonyl wherein the amino group is optionally mono- or di-substituted by (C₁₋₄)alkyl or (C₂₋₄)alkenyl; aryl; aryl(C₁₋₄)alkyl; aryl(C₁₋₄)alkoxy; or R⁴ and R⁵ may together represent oxo;
- each R⁶ is independently hydrogen; trifluoromethyl; (C₁₋₄)alkyl unsubstituted or substituted by hydroxy, (C₁₋₆)alkoxy, (C₁₋₆)alkylthio, halo or trifluoromethyl; (C₂₋₄)alkenyl; aryl; aryl(C₁₋₄)alkyl; arylcarbonyl; heteroarylcarbonyl; (C₁₋₄)alkoxycarbonyl; (C₁₋₄)alkylcarbonyl; formyl; (C₁₋₆)alkylsulphonyl; or aminocarbonyl wherein the amino group is optionally substituted by (C₁₋₄)alkoxycarbonyl, (C₁₋₄)alkylcarbonyl, (C₂₋₄)alkenyloxycarbonyl, (C₂₋₄)alkenylcarbonyl, (C₁₋₄)alkyl or (C₂₋₄)alkenyl and optionally further substituted by (C₁₋₄)alkyl or (C₂₋₄)alkenyl; and
- each x is independently 0, 1, or 2; or a pharmaceutically acceptable salt thereof.

Also included in this invention are pharmaceutically acceptable addition salts, complexes or prodrugs of the compounds of this invention. Prodrugs are considered to be any covalently bonded carriers which release the active parent drug according to formula (I) *in vivo*.

The invention also provides a pharmaceutical composition, in particular for use in the treatment of bacterial infections in mammals, particularly humans, comprising a compound of formula (I), or a pharmaceutically acceptable derivative thereof, and a pharmaceutically acceptable carrier.

The invention further provides a method of treatment of bacterial infections in mammals, particularly in humans, which method comprises the administration to a mammal in need of such treatment an effective amount of a compound of formula (I), or a pharmaceutically acceptable derivative thereof.

5

Preferably Z_5 is CH or N, Z_3 is CH or CF and Z_1 , Z_2 and Z_4 are each CH, or Z_1 is N, Z_3 is CH or CF and Z_2 , Z_4 and Z_5 are each CH.

When R^1 or R^{1a} is substituted alkoxy it is preferably (C_{2-6}) alkoxy substituted by optionally N-substituted amino, guanidino or amidino, or (C_{1-6}) alkoxy substituted by piperidyl. Suitable examples of R^1 and R^{1a} alkoxy include methoxy, trifluoromethoxy, n-propyloxy, iso-butyloxy, aminoethyloxy, aminopropyloxy, aminobutyloxy, aminopentyloxy, guanidinopropyloxy, piperidin-4-ylmethyloxy, phthalimido pentyloxy or 2-aminocarbonylprop-2-oxy.

15

Preferably R^1 and R^{1a} are independently methoxy, amino (C_{3-5}) alkyloxy, guanidino (C_{3-5}) alkyloxy, piperidyl (C_{3-5}) alkyloxy, nitro or fluoro. More preferably R^1 and R^{1a} are independently methoxy, amino (C_{3-5}) alkyloxy or guanidino (C_{3-5}) alkyloxy. Most preferably R^1 is methoxy and R^{1a} is H or when Z^3 is CR^{1a} it may be CF.

20

Preferably W_1 - W_4 are independently CR^3 ; W_1 , W_3 and W_4 are N and W_2 is CR^3 ; W_2 is N and W_1 , W_3 and W_4 are independently CR^3 ; W_3 is N and W_1 , W_2 and W_4 are independently CR^3 ; or W_4 is N and W_1 - W_3 are independently CR^3 .

25

Preferably R^3 is hydrogen, (C_{1-6}) alkoxy, or NH_2 .

Most preferably R^3 is hydrogen.

Preferably each R is independently selected from hydrogen, (C₁₋₆)alkyl, CONH₂, COOH, hydroxy, halogen, and (C₁₋₆)alkoxy.

Most preferably each R is hydrogen.

Preferably in the heterocyclic ring (A) Y² has 3-5 atoms, more preferably 4 atoms, including CH, NR⁶, O or S bonded to X⁴ and NHCO bonded via N to X³, or O or NH bonded to X³. Ring (a) is preferably substituted and unsubstituted phenyl and pyridine. Preferably ring (b) is substituted and unsubstituted pyridine, dioxane, piperidine, morpholin-3-one, thiomorpholin-3-one, oxazolidin-2-one, thiadiazole, and thiazepan-5-one. Examples of ring (A) groups include substituted or unsubstituted: 1,1,3-trioxo-1,2,3,4-tetrahydro-6-benzo[1,4]thiazin-3-one-6-yl, benzo[1,3]dioxol-5-yl, 4H-benzo[1,4]oxazin-3-one-6-yl, 2,3-dihydro-benzo[1,4]dioxin-6-yl, 2-oxo-2,3-dihydro-benzooxazol-6-yl, 3-substituted-3H-benzooxazol-2-one-6-yl, 3-substituted-3H-benzooxazole-2-thione-6-yl, 3-substituted-3H-benzothiazol-2-one-6-yl, 4H-benzo[1,4]oxazin-3-one-6-yl (3-oxo-3,4-dihydro-2H-benzo[1,4]oxazin-6-yl), 4H-benzo[1,4]thiazin-3-one-6-yl (3-oxo-3,4-dihydro-2H-benzo[1,4]thiazin-6-yl), 4H-benzo[1,4]oxazin-3-one-7-yl, 4-oxo-2,3,4,5-tetrahydro-benzo[b][1,4]thiazepine-7-yl, 5-oxo-2,3-dihydro-5H-thiazolo[3,2-a]pyrimidin-6-yl, benzo[1,3]dioxol-5-yl, 1H-pyrido[2,3-b][1,4]thiazin-2-one-7-yl (2-oxo-2,3-dihydro-1H-pyrido[2,3-b]thiazin-7-yl), 2,3-dihydro-1H-pyrido[2,3-b][1,4]thiazin-7-yl, 2-oxo-2,3-dihydro-1H-pyrido[3,4-b]thiazin-7-yl, 2,3-dihydro-[1,4]dioxino[2,3-b]pyridin-6-yl, 2,3-dihydro-[1,4]dioxino[2,3-c]pyridin-7-yl, 2,3-dihydro-[1,4]dioxino[2,3-b]pyridin-7-yl, 3,4-dihydro-2H-benzo[1,4]oxazin-6-yl, 3,4-dihydro-2H-benzo[1,4]thiazin-6-yl, 3-oxo-3,4-dihydro-2H-pyrido[3,2-b][1,4]oxazin-6-yl, 3,4-dihydro-2H-pyrido[3,2-b][1,4]thiazin-6-yl, 3-oxo-3,4-dihydro-2H-pyrido[3,2-b][1,4]thiazin-6-yl, 3,4-dihydro-1H-quinolin-2-one-7-yl, 3,4-dihydro-1H-quinoxalin-2-one-7-yl, 6,7-dihydro-4H-pyrazolo[1,5-a]pyrimidin-5-one-2-yl, 5,6,7,8-tetrahydro-[1,8]naphthyridin-2-yl, 2-oxo-3,4-dihydro-1H-[1,8]naphthyridin-6-yl, 4H-pyrido[3,2-b][1,4]thiazin-3-one-6-yl, 4H-pyrido[3,2-b][1,4]oxazin-3-one-6-yl, 1,2,3,4-tetrahydro-[1,8]naphthyridine-7-yl, 1H-pyrido[3,2-b][1,4]thiazin-2-one-7-yl, and 6-fluoro-2,3-dihydrobenzo[1,4]dioxine-7-yl.

R⁴ and R⁵ are preferably independently selected from hydrogen, halo, hydroxy, (C₁₋₄)alkoxy, trifluoromethoxy, nitro, cyano, aryl(C₁₋₄)alkoxy and

(C₁₋₄)alkylsulphonyl. More preferably R⁵ is hydrogen.

More preferably each R⁴ is selected from hydrogen, chloro, fluoro, hydroxy, methoxy, trifluoromethoxy, benzyloxy, nitro, cyano and methylsulphonyl. Most preferably R⁴ is selected from hydrogen, fluorine or nitro.

- 5 R⁶ is preferably H if in ring (a) or in addition (C₁₋₄)alkyl such as methyl or isopropyl when in ring (b). More preferably, in ring (b) R⁶ is H when NR⁶ is bonded to X³ and (C₁₋₄)alkyl when NR⁶ is bonded to X⁵.

Most preferred examples of R² are:

- 10 4*H*-benzo[1,4]thiazin-3-one-6-yl,
 4*H*-pyrido[3,2-*b*][1,4]thiazin-3-one-6-yl,
 4*H*-pyrido[3,2-*b*][1,4]oxazin-3-one-6-yl,
 1,2,3,4-tetrahydro-[1,8]naphthyridine-7-yl,
 1*H*-pyrido[3,2-*b*][1,4]thiazin-2-one-7-yl,
 15 4*H*-benzo[1,4]oxazin-3-one-6-yl, and
 6-fluoro-2,3-dihydrobenzo[1,4]dioxine-7-yl.

Preferred compounds of this invention are:

- 20 6-({2-[4-(6-Methoxy-[1,5]naphthyridin-4-yl)phenyl]ethylamino)methyl)-4*H*-benzo[1,4]thiazin-3-one;
 6-({2-[4-(6-Methoxy-[1,5]naphthyridin-4-yl)phenyl]ethylamino)methyl)-4*H*-pyrido[3,2-*b*][1,4]thiazin-3-one;
 6-({2-[4-(6-Methoxy-[1,5]naphthyridin-4-yl)phenyl]ethylamino)methyl)-4*H*-pyrido[3,2-*b*][1,4]oxazin-3-one;
 25 3-Oxo-3,4-dihydro-2*H*-benzo[1,4]thiazine-6-sulfonic acid {2-[4-(6-methoxy-[1,5]naphthyridin-4-yl)phenyl]ethyl}amide;
 {2-[4-(6-Methoxy-[1,5]naphthyridin-4-yl)phenyl]ethyl} (5,6,7,8-tetrahydro[1,8]naphthyridin-2-ylmethyl)amine;
 6-([4-(6-Methoxy-[1,5]naphthyridin-4-yl)benzylamino)methyl)-4*H*-
 30 benzo[1,4]thiazin-3-one;
 7-({2-[4-(6-Methoxy-[1,5]naphthyridin-4-yl)phenyl]ethylamino)methyl)-1*H*-pyrido[3,2-*b*][1,4]thiazin-2-one;
 6-([2-[4-(6-Methoxy-[1,5]naphthyridin-4-yl)benzylamino]ethyl)-4*H*-benzo[1,4]oxazin-3-one;

- 6-{2-[4-(6-Methoxy-[1,5]naphthyridin-4-yl)benzylamino]ethyl}-4*H*-benzo[1,4]thiazin-3-one;
 (7-Fluoro-2,3-dihydrobenzo[1,4]dioxin-6-ylmethyl){2-[6-(6-methoxy[1,5]naphthyridin-4-yl)[1,2,4]triazin-3-yl]ethyl}amine;
 5 6-({2-[4-(6-Methoxyquinolin-4-yl)phenyl]ethylamino)methyl)-4*H*-pyrido[3,2-*b*][1,4]oxazin-3-one;
 6-({2-[4-(6,8-difluoroquinolin-4-yl)phenyl]ethylamino)methyl)-4*H*-pyrido[3,2-*b*][1,4]thiazin-3-one;
 6-({2-[4-(8-Fluoro-6-methoxyquinolin-4-yl)phenyl]ethylamino)methyl)-4*H*-
 10 pyrido[3,2-*b*][1,4]thiazin-3-one;
 6-({2-[6-(6-methoxy-[1,5]naphthyridin-4-yl)pyridin-3-yl]ethylamino)methyl)-4*H*-pyrido[3,2-*b*][1,4]thiazin-3-one;
 6-({2-[5-(6-methoxy-[1,5]naphthyridin-4-yl)pyridin-2-yl]ethylamino)methyl)-4*H*-pyrido[3,2-*b*][1,4]thiazin-3-one;
 15 6-({2-[6-(6-methoxy-[1,5]naphthyridin-4-yl)pyridin-3-yl]ethylamino)methyl)-4*H*-pyrido[3,2-*b*][1,4]oxazin-3-one;
N-(2,3-dihydro[1,4]dioxino[2,3-*c*]pyridin-7-ylmethyl)-2-{6-[6-(methyloxy)-1,5-naphthyridin-4-yl]-3-pyridinyl}ethanamine;
N-(2,3-dihydro[1,4]dioxino[2,3-*c*]pyridin-7-ylmethyl)-2-{5-[6-(methyloxy)-1,5-naphthyridin-4-yl]-2-pyridinyl}ethanamine;
 20 *N*-(2-{6-[6-(methyloxy)-1,5-naphthyridin-4-yl]-3-pyridinyl}ethyl)-3-oxo-3,4-dihydro-2*H*-pyrido[3,2-*b*][1,4]thiazine-6-carboxamide; and
N-(2-{5-[6-(methyloxy)-1,5-naphthyridin-4-yl]-2-pyridinyl}ethyl)-3-oxo-3,4-dihydro-2*H*-pyrido[3,2-*b*][1,4]thiazine-6-carboxamide;
 25 or a pharmaceutically acceptable salt thereof.

Unless otherwise defined, the term (C₁₋₆)alkyl when used alone or when forming part of other groups (such as the 'alkoxy' group) includes substituted or unsubstituted, straight or branched chain alkyl groups containing 1 to 6 carbon
 30 atoms. Examples of (C₁₋₆)alkyl include methyl, ethyl, n-propyl, isopropyl, n-butyl, isobutyl and tert-butyl groups.

The term (C₂₋₆)alkenyl means a substituted or unsubstituted alkyl group of 2 to 6 carbon atoms, wherein one carbon-carbon single bond is replaced by a carbon-carbon double bond. Examples of (C₂₋₆)alkenyl include ethylene, 1-
 35 propene,

2-propene, 1-butene, 2-butene, isobutene and the several isomeric pentenes and hexenes. Both cis and trans isomers are included.

The term (C₃₋₇)cycloalkyl refers to substituted or unsubstituted carbocyclic system of three to seven carbon atoms, which may contain up to two unsaturated carbon-carbon bonds. Examples of (C₃₋₇)cycloalkyl include cyclopropyl, cyclobutyl, cyclopentyl, cyclopentenyl, cyclohexyl, cyclohexenyl, and cycloheptyl.

Unless otherwise defined, suitable substituents for any (C₁₋₆)alkyl, (C₂₋₆)alkenyl, and (C₃₋₇)cycloalkyl groups includes up to three substituents selected from the group consisting of hydroxy, halogen, nitro, cyano, carboxy, amino, amidino, sulphonamido, unsubstituted (C₁₋₆)alkoxy, trifluoromethyl, acyloxy, guanidino, unsubstituted (C₃₋₇)cycloalkyl, aryl, and heterocyclic.

Halo or halogen includes fluoro, chloro, bromo and iodo.

Haloalkyl moieties include 1-3 halogen atoms.

Unless otherwise defined, the term "heterocyclic" as used herein includes optionally substituted aromatic and non-aromatic, single and fused, rings suitably containing up to four heteroatoms in each ring selected from oxygen, nitrogen and sulphur, which rings may be unsubstituted or C-substituted by, for example, up to three groups selected from (C₁₋₄)alkylthio; halo; carboxy(C₁₋₄)alkyl; halo(C₁₋₄)alkoxy; halo(C₁₋₄)alkyl; (C₁₋₄)alkyl; (C₂₋₄)alkenyl; (C₁₋₄)alkoxycarbonyl; formyl; (C₁₋₄)alkylcarbonyl; (C₂₋₄)alkenyloxycarbonyl; (C₂₋₄)alkenylcarbonyl; (C₁₋₄)alkylcarbonyloxy; (C₁₋₄)alkoxycarbonyl(C₁₋₄)alkyl; hydroxy; hydroxy(C₁₋₄)alkyl; mercapto(C₁₋₄)alkyl; (C₁₋₄)alkoxy; nitro; cyano, carboxy; amino or aminocarbonyl optionally substituted as for corresponding substituents in R³; (C₁₋₄)alkylsulphonyl; (C₂₋₄)alkenylsulphonyl; or aminosulphonyl wherein the amino group is optionally substituted by (C₁₋₄)alkyl or (C₂₋₄)alkenyl; optionally substituted aryl, aryl(C₁₋₄)alkyl or aryl(C₁₋₄)alkoxy and oxo groups.

Each heterocyclic ring suitably has from 4 to 7, preferably 5 or 6, ring atoms. A fused heterocyclic ring system may include carbocyclic rings and need include only one heterocyclic ring.

Compounds within the invention containing a heterocyclyl group may occur in two or more tautomeric forms depending on the nature of the heterocyclyl group; all such tautomeric forms are included within the scope of the invention.

Where an amino group forms part of a single or fused non-aromatic heterocyclic ring as defined above suitable optional substituents in such substituted amino groups include H; trifluoromethyl; (C₁₋₄)alkyl optionally substituted by hydroxy, (C₁₋₆)alkoxy, (C₁₋₆)alkylthio, halo or trifluoromethyl; (C₂₋₄)alkenyl; aryl; aryl (C₁₋₄)alkyl; (C₁₋₄)alkoxycarbonyl; (C₁₋₄)alkylcarbonyl; formyl; (C₁₋₆)alkylsulphonyl; or aminocarbonyl wherein the amino group is optionally substituted by (C₁₋₄)alkoxycarbonyl, (C₁₋₄)alkylcarbonyl, (C₂₋₄)alkenyloxycarbonyl, (C₂₋₄)alkenylcarbonyl, (C₁₋₄)alkyl or (C₂₋₄)alkenyl and optionally further substituted by (C₁₋₄)alkyl or (C₂₋₄)alkenyl.

When used herein the term "aryl", includes optionally substituted phenyl and naphthyl.

Aryl groups may be optionally substituted with up to five, preferably up to three, groups selected from (C₁₋₄)alkylthio; halo; carboxy(C₁₋₄)alkyl; halo(C₁₋₄)alkoxy; halo(C₁₋₄)alkyl; (C₁₋₄)alkyl; (C₂₋₄)alkenyl; (C₁₋₄)alkoxycarbonyl; formyl; (C₁₋₄)alkylcarbonyl; (C₂₋₄)alkenyloxycarbonyl; (C₂₋₄)alkenylcarbonyl; (C₁₋₄)alkylcarbonyloxy; (C₁₋₄)alkoxycarbonyl(C₁₋₄)alkyl; hydroxy; hydroxy(C₁₋₄)alkyl; mercapto(C₁₋₄)alkyl; (C₁₋₄)alkoxy; nitro; cyano; carboxy; amino or aminocarbonyl optionally substituted as for corresponding substituents in R³; (C₁₋₄)alkylsulphonyl; (C₂₋₄)alkenylsulphonyl; or aminosulphonyl wherein the amino group is optionally substituted by (C₁₋₄)alkyl or (C₂₋₄)alkenyl; phenyl, phenyl(C₁₋₄)alkyl or phenyl(C₁₋₄)alkoxy

The term "acyl" includes formyl and (C₁₋₆)alkylcarbonyl group.


Some of the compounds of this invention may be crystallised or recrystallised from solvents such as aqueous and organic solvents. In such cases solvates may be formed. This invention includes within its scope stoichiometric solvates including hydrates as well as compounds containing variable amounts of water that may be produced by processes such as lyophilisation.

Since the compounds of formula (I) are intended for use in pharmaceutical compositions it will readily be understood that they are each provided in substantially pure form, for example at least 60% pure, more suitably at least 75% pure and preferably at least 85%, especially at least 98% pure (% are on a weight for weight basis). Impure preparations of the compounds may be used for

preparing the more pure forms used in the pharmaceutical compositions; these less pure preparations of the compounds should contain at least 1%, more suitably at least 5% and preferably from 10 to 59% of a compound of the formula (I) or pharmaceutically acceptable derivative thereof.

- 5 Pharmaceutically acceptable derivatives of the above-mentioned compounds of formula (I) include the free base form or their acid addition or quaternary ammonium salts, for example their salts with mineral acids e.g. hydrochloric, hydrobromic, sulphuric nitric or phosphoric acids, or organic acids, e.g. acetic, fumaric, succinic, maleic, citric, benzoic, p-toluenesulphonic, methanesulphonic, naphthalenesulphonic acid or tartaric acids. Compounds of formula (I) may also be prepared as the N-oxide. Compounds of formula (I) having a free carboxy group may also be prepared as an *in vivo* hydrolysable ester. The invention extends to all such derivatives.

- 15 Examples of suitable pharmaceutically acceptable *in vivo* hydrolysable ester-forming groups include those forming esters which break down readily in the human body to leave the parent acid or its salt. Suitable groups of this type include those of part formulae (i), (ii), (iii), (iv) and (v):



20




wherein R^a is hydrogen, (C₁₋₆) alkyl, (C₃₋₇) cycloalkyl, methyl, or phenyl, R^b is (C₁₋₆) alkyl, (C₁₋₆) alkoxy, phenyl, benzyl, (C₃₋₇) cycloalkyl, (C₃₋₇) cycloalkyloxy, (C₁₋₆) alkyl (C₃₋₇) cycloalkyl, 1-amino (C₁₋₆) alkyl, or

- 5 1-(C₁₋₆ alkyl)amino (C₁₋₆) alkyl; or R^a and R^b together form a 1,2-phenylene group optionally substituted by one or two methoxy groups; R^c represents (C₁₋₆) alkylene optionally substituted with a methyl or ethyl group and R^d and R^e independently represent (C₁₋₆) alkyl; R^f represents (C₁₋₆) alkyl; R^g represents hydrogen or phenyl optionally substituted by up to three groups selected from
 10 halogen, (C₁₋₆) alkyl, or (C₁₋₆) alkoxy; Q is oxygen or NH; R^h is hydrogen or (C₁₋₆) alkyl; Rⁱ is hydrogen, (C₁₋₆) alkyl optionally substituted by halogen, (C₂₋₆) alkenyl, (C₁₋₆) alkoxycarbonyl, aryl or heteroaryl; or R^h and Rⁱ together form (C₁₋₆) alkylene; R^j represents hydrogen, (C₁₋₆) alkyl or (C₁₋₆) alkoxycarbonyl; and R^k represents (C₁₋₈) alkyl, (C₁₋₈) alkoxy, (C₁₋₆) alkoxy(C₁₋₆)alkoxy or aryl.

- 15 Examples of suitable *in vivo* hydrolysable ester groups include, for example, acyloxy(C₁₋₆)alkyl groups such as acetoxymethyl, pivaloyloxymethyl, α-acetoxyethyl, α-pivaloyloxyethyl, 1-(cyclohexylcarbonyloxy)prop-1-yl, and (1-aminoethyl)carbonyloxymethyl; (C₁₋₆)alkoxycarbonyloxy(C₁₋₆)alkyl groups, such as ethoxycarbonyloxymethyl, α-ethoxycarbonyloxyethyl and
 20 propoxycarbonyloxyethyl; di(C₁₋₆)alkylamino(C₁₋₆)alkyl especially di(C₁₋₄)alkylamino(C₁₋₄)alkyl groups such as dimethylaminomethyl, dimethylaminoethyl, diethylaminomethyl or diethylaminoethyl; 2-((C₁₋₆)alkoxycarbonyl)-2-(C₂₋₆)alkenyl groups such as 2-(isobutoxycarbonyl)pent-2-enyl and 2-(ethoxycarbonyl)but-2-enyl; lactone groups such as phthalidyl and
 25 dimethoxyphthalidyl.

A further suitable pharmaceutically acceptable *in vivo* hydrolysable ester-forming group is that of the formula:



wherein R^k is hydrogen, (C₁₋₆) alkyl or phenyl.

- 5 Certain of the above-mentioned compounds of formula (I) may exist in the form of optical isomers, e.g. diastereoisomers and mixtures of isomers in all ratios, e.g. racemic mixtures. The invention includes all such forms, in particular the pure isomeric forms. For examples the invention includes compound in which an A-B group CH(OH)-CH₂ is in either isomeric configuration the *R*-isomer is preferred.
- 10 The different isomeric forms may be separated or resolved one from the other by conventional methods, or any given isomer may be obtained by conventional synthetic methods or by stereospecific or asymmetric syntheses.


15 The following examples illustrate the preparation of certain compounds of formula (I) and the activity of certain compounds of formula (I) against various bacterial organisms.

 Certain reagents are abbreviated herein. DCC refers to dicyclohexylcarbodiimide, DMAP refers to dimethylaminopyridine, DIEA refers to diisopropylethyl amine, EDC refers to 1-(3-dimethylaminopropyl)-3-ethylcarbodiimide, hydrochloride. HOBt refers to 1-hydroxybenzotriazole, THF refers to tetrahydrofuran, DIEA refers to diisopropylethylamine, DEAD refers to diethyl azodicarboxylate, PPh₃ refers to triphenylphosphine, DIAD refers to diisopropyl azodicarboxylate, DME refers to dimethoxyethane, DMF refers to dimethylformamide, NBS refers to N-bromosuccinimide, Pd/C refers to a palladium on carbon catalyst, PPA refers to polyphosphoric acid, DPPA refers to

20 diphenylphosphoryl azide, BOP refers to benzotriazol-1-yloxy-tris(dimethyl-amino)phosphonium hexafluorophosphate, HF refers to hydrofluoric acid, TEA refers to triethylamine, TFA refers to trifluoroacetic acid, PCC refers to pyridinium chlorochromate.

30 The compounds of the present invention were prepared by the methods illustrated in Schemes I-VI.


Scheme I



- 5 **Reagents and conditions:** (a) bis(pinacolato)diboron, dppf, PdCl₂(dppf), KOAc, dioxane; then dppf, PdCl₂(dppf), K₂CO₃, [2-(4-bromophenyl)ethyl]carbamic acid *tert*-butyl ester (b) trifluoroacetic acid, CH₂Cl₂; (c) 3-oxo-3,4-dihydro-2H-benzo[1,4]thiazine-6-carboxaldehyde, CH₂Cl₂, EtOH; then NaBH₄, EtOH.
- 10 Triflate (I-1) is reacted under Suzuki coupling conditions in a one-pot procedure (Ishiyama, T.; Itoh, Y; Kitano, T.; Miyaura, N. *Tetrahedron Lett.* **1997**, Vol. 38, No. 19, pp. 3447-3450) with an aromatic halide or aromatic triflate to afford I-2. Removal of the Boc protecting group is carried out under standard acidic conditions to give the free amine I-3. The use of protecting groups to mask reactive
- 15 functionality is well-known to those of skill in the art, and other protecting groups are listed in standard reference volumes, such as Greene, "Protective Groups in Organic Synthesis" (published by Wiley-Interscience). The primary amine derivative is then converted to a secondary amine I-4 by reaction with an aldehyde and a suitable reducing agent. For example, 2-[4-(6-methoxy[1,5]naphthylidin-4-yl)phenyl]ethylamine is converted to an imine by reaction with an aldehyde in protic
- 20 or aprotic solvents such as DMF, CH₂Cl₂, EtOH or CH₃CN. The imine is

- subsequently or simultaneously reacted with a suitable reducing agent such as NaBH_4 , $\text{NaBH}(\text{OAc})_3$ or NaBH_3CN in solvent. Depending on whether acid neutralization is required, an added base, such as triethylamine (Et_3N), diisopropylethylamine ($(i\text{-Pr})_2\text{NEt}$), or K_2CO_3 , may be used. Many additional
- 5 methods for reductive aminations are known, and can be found in standard reference books, such as "Compendium of Organic Synthetic Methods", Vol. I - VI (published by Wiley-Interscience).

Scheme II



10

Reagents and conditions: (a) β -alanine ethyl ester, Et_3N , DMF; then NaBH_4 , EtOH; (b) di-*tert*-butyl dicarbonate, MeOH; (c) N_2H_4 , EtOH; (d) 2-bromo-1-(6-methoxy[1,5]naphthyridin-4-yl)ethanone, DMF; (e) trifluoroacetic acid, CH_2Cl_2 .

15

Aldehyde (II-1) is reacted with a primary amine to form an imine which can be reduced *in situ* to a secondary amine (II-2) by reaction with a suitable reducing agent. For example, β -alanine ethyl ester is converted to an imine by reaction with an aldehyde in protic or aprotic solvents such as DMF, CH_2Cl_2 , EtOH or CH_3CN .


The imine is subsequently or simultaneously reacted with a suitable reducing agent such as NaBH_4 , $\text{NaBH}(\text{OAc})_3$ or NaBH_3CN in solvent. Depending on whether acid neutralization is required, an added base, such as triethylamine (Et_3N), diisopropylethylamine ($(i\text{-Pr})_2\text{NEt}$), or K_2CO_3 , may be used. Many additional

5 methods for reductive aminations are known, and can be found in standard reference books, such as "Compendium of Organic Synthetic Methods", Vol. I - VI (published by Wiley-Interscience). The amine functionality is protected with a Boc protecting group. The use of protecting groups to mask reactive functionality is well-known to those of skill in the art, and other protecting groups are listed in

10 standard reference volumes, such as Greene, "Protective Groups in Organic Synthesis" (published by Wiley-Interscience). The ethyl ester (**II-3**) is reacted with hydrazine to give the hydrazide **II-4** which is subsequently reacted with an α -haloketone to afford the cyclocondensation product **II-5**. Removal of the Boc protecting group is carried out under standard acidic conditions to give the free

15 amine **II-6**.

Scheme III



Reagents and conditions: (a) 6-(2-chloroethyl)-4*H*-benzo[1,4]oxazin-3-one, NaI , K_2CO_3 , CH_3CN , 80°C


Amine (**III-1**) is reacted with a primary alkyl halide or similar functionality, such as alkyl tosylates or alkyl mesylates, to form a secondary amine (**III-2**). For

25 example, 6-(2-chloroethyl)-4*H*-benzo[1,4]oxazin-3-one is heated in protic or aprotic

solvents such as DMF, CH_2Cl_2 , EtOH or CH_3CN with a suitable amine using NaI as a halogen exchange catalyst. Depending on whether acid neutralization is required, an added base, such as triethylamine (Et_3N), diisopropylethylamine ($(i\text{-Pr})_2\text{NEt}$), or K_2CO_3 , may be used.

5

Scheme IV




10

Reagents and conditions: (a) NBS, benzoyl peroxide, CCl_4 , 70 °C; (b) KCN, EtOH, H_2O , 60 °C; (c) B_2H_6 , THF, RT; (d) $(\text{Boc})_2\text{O}$, THF, RT.

Methyl pyridine (IV-1 or IV-4) is reacted under radical halogen generating conditions to afford the methyl bromide product (IV-2 or IV-6). Benzylic halogenation under radical conditions is well-known to those in the art. The methyl bromides (IV-2 or IV-6) are then treated with a cyano nucleophile in an appropriate solvent (eg, $\text{H}_2\text{O}/\text{MeOH}$, DMF) to give the nitrile products (IV-3 or IV-7) via a standard $\text{S}_{\text{N}}2$ displacement chemistry which is exemplified in all introductory chemistry textbooks. Reduction of the nitrile functionality using a suitable reducing agent such as (LiAlH_4 , B_2H_6 , $\text{H}_2\text{-Pd/C}$, etc.) see ("Borane Reagents" Best

Synthetic Methods, A. Pelter, K. Smith, H.C. Brown; Academic Press) provides a primary amine. The primary amine can be protected with a suitably reactive reagent such as (Boc)₂O, in situ to provide the carbamates (IV-4 or IV-8).

5

Scheme V

10

Reagents and conditions: (a) bis(pinacolato)diboron, dppf, PdCl₂(dppf), KOAc, dioxane; then dppf, PdCl₂(dppf), K₂CO₃, V-3; (b) HCl, dioxane; (c) 3-oxo-3,4-dihydro-2H-pyrido[1,4]thiazine-6-carboxaldehyde, CH₂Cl₂, EtOH; then NaBH₄, EtOH.


15

Triflate (V-1) is reacted under Suzuki coupling conditions in a one-pot procedure (Ishiyama, T.; Itoh, Y; Kitano, T.; Miyaura, N. *Tetrahedron Lett.* **1997**, Vol. 38, No. 19, pp. 3447-3450) with an aromatic halide or aromatic triflate to afford V-2. Removal of the Boc protecting group is carried out under standard acidic conditions to give the free amine V-3. The use of protecting groups to mask reactive functionality is well-known to those of skill in the art, and other protecting

20

groups are listed in standard reference volumes, such as Greene, "Protective Groups in Organic Synthesis" (published by Wiley-Interscience). The primary amine derivative is then converted to a secondary amine **V-4** by reaction with an aldehyde and a suitable reducing agent. For example, 2-[4-(6-methoxy[1,5]naphthyridin-4-yl)phenyl]ethylamine is converted to an imine by reaction with an aldehyde in protic or aprotic solvents such as DMF, CH₂Cl₂, EtOH or CH₃CN. The imine is subsequently or simultaneously reacted with a suitable reducing agent such as NaBH₄, NaBH(OAc)₃ or NaBH₃CN in solvent. Depending on whether acid neutralization is required, an added base, such as triethylamine (Et₃N), diisopropylethylamine ((i-Pr)₂NEt), or K₂CO₃, may be used. Many additional methods for reductive aminations are known, and can be found in standard reference books, such as "Compendium of Organic Synthetic Methods", Vol. I - VI (published by Wiley-Interscience).

15

Scheme VI

20

Reagents and conditions: (a) EDC, HOBt, (i-Pr)₂NEt, DMF, 3-oxo-3,4-dihydro-2H-pyrido[3,2-b][1,4]thiazine-6-carboxylic acid.

A suitable carboxylic acid, for instance 3-oxo-3,4-dihydro-2H-pyrido[3,2-b][1,4]thiazine-6-carboxylic acid, is converted to an activated form using, for example, EDC and HOBt, or SOCl₂, and the activated form is subsequently

reacted with an appropriate amine, for instance amine (V-3), in a suitable solvent such as DMF, CH₂Cl₂, or CH₃CN, to afford VI-1. Depending on whether acid neutralization is required, an added base, such as triethylamine (Et₃N), diisopropylethylamine ((*i*-Pr)₂NEt), or pyridine, may be used. Many additional
5 methods for converting a carboxylic acid to an amide are known, and can be found in standard reference books, such as "Compendium of Organic Synthetic Methods", Vol. I - VI (published by Wiley-Interscience), or Bodansky, "The Practice of Peptide Synthesis" (published by Springer-Verlag).

The pharmaceutical compositions of the invention include those in a form
10 adapted for oral, topical or parenteral use and may be used for the treatment of bacterial infection in mammals including humans.

The antibiotic compounds according to the invention may be formulated for administration in any convenient way for use in human or veterinary medicine, by analogy with other antibiotics.

15 The composition may be formulated for administration by any route, such as oral, topical or parenteral. The compositions may be in the form of tablets, capsules, powders, granules, lozenges, creams or liquid preparations, such as oral or sterile parenteral solutions or suspensions.

The topical formulations of the present invention may be presented as, for
20 instance, ointments, creams or lotions, eye ointments and eye or ear drops, impregnated dressings and aerosols, and may contain appropriate conventional additives such as preservatives, solvents to assist drug penetration and emollients in ointments and creams.

The formulations may also contain compatible conventional carriers, such
25 as cream or ointment bases and ethanol or oleyl alcohol for lotions. Such carriers may be present as from about 1% up to about 98% of the formulation. More usually they will form up to about 80% of the formulation.

Tablets and capsules for oral administration may be in unit dose presentation form, and may contain conventional excipients such as binding
30 agents, for example syrup, acacia, gelatin, sorbitol, tragacanth, or polyvinylpyrrolidone; fillers, for example lactose, sugar, maize-starch, calcium phosphate, sorbitol or glycine; tableting lubricants, for example magnesium stearate, talc, polyethylene glycol or silica; disintegrants, for example potato starch; or acceptable wetting agents such as sodium lauryl sulphate. The tablets may be

coated according to methods well known in normal pharmaceutical practice. Oral liquid preparations may be in the form of, for example, aqueous or oily suspensions, solutions, emulsions, syrups or elixirs, or may be presented as a dry product for reconstitution with water or other suitable vehicle before use. Such liquid preparations may contain conventional additives, such as suspending agents, for example sorbitol, methyl cellulose, glucose syrup, gelatin, hydroxyethyl cellulose, carboxymethyl cellulose, aluminium stearate gel or hydrogenated edible fats, emulsifying agents, for example lecithin, sorbitan monooleate, or acacia; non-aqueous vehicles (which may include edible oils), for example almond oil, oily esters such as glycerine, propylene glycol, or ethyl alcohol; preservatives, for example methyl or propyl p-hydroxybenzoate or sorbic acid, and, if desired, conventional flavouring or colouring agents.

Suppositories will contain conventional suppository bases, e.g. cocoa-butter or other glyceride.

For parenteral administration, fluid unit dosage forms are prepared utilizing the compound and a sterile vehicle, water being preferred. The compound, depending on the vehicle and concentration used, can be either suspended or dissolved in the vehicle. In preparing solutions the compound can be dissolved in water for injection and filter sterilised before filling into a suitable vial or ampoule and sealing.

Advantageously, agents such as a local anaesthetic, preservative and buffering agents can be dissolved in the vehicle. To enhance the stability, the composition can be frozen after filling into the vial and the water removed under vacuum. The dry lyophilized powder is then sealed in the vial and an accompanying vial of water for injection may be supplied to reconstitute the liquid prior to use. Parenteral suspensions are prepared in substantially the same manner except that the compound is suspended in the vehicle instead of being dissolved and sterilization cannot be accomplished by filtration. The compound can be sterilised by exposure to ethylene oxide before suspending in the sterile vehicle. Advantageously, a surfactant or wetting agent is included in the composition to facilitate uniform distribution of the compound.

The compositions may contain from 0.1% by weight, preferably from 10-60% by weight, of the active material, depending on the method of administration. Where the compositions comprise dosage units, each unit will preferably contain from 50-500 mg of the active ingredient. The dosage as

employed for adult human treatment will preferably range from 100 to 3000 mg per day, for instance 1500 mg per day depending on the route and frequency of administration. Such a dosage corresponds to 1.5 to 50 mg/kg per day. Suitably the dosage is from 5 to 20 mg/kg per day.

- 5 No toxicological effects are indicated when a compound of formula (I) or a pharmaceutically acceptable salt or *in vivo* hydrolysable ester thereof is administered in the above-mentioned dosage range.

- The compound of formula (I) may be the sole therapeutic agent in the compositions of the invention or a combination with other antibiotics or with a
10 β-lactamase inhibitor may be employed.

 Compounds of formula (I) are active against a wide range of organisms including both Gram-negative and Gram-positive organisms.

Biological Activity

- 15 Antimicrobial Activity Assay:

- Whole-cell antimicrobial activity was determined by broth microdilution using the National Committee for Clinical Laboratory Standards (NCCLS) recommended procedure, Document M7-A4, "Methods for Dilution Susceptibility Tests for Bacteria
20 that Grow Aerobically". The compounds were tested in serial two-fold dilutions ranging from 0.016 to 64 mcg/mL. Compounds were evaluated against a panel of Gram-(+) organisms, including *Staphylococcus aureus* WCUH29, *Staphylococcus epidermidis* CL7, *Streptococcus pneumoniae* 1629, *Streptococcus pyogenes* CN
10 10, *Enterococcus faecalis* 2, and *Enterococcus faecium* 8. In addition, compounds
25 were evaluated against a panel of Gram-(-) strains including *Haemophilus influenzae* NEMC1, *E. coli* 7623 AcrABEFD+, and *Moraxella catarrhalis* Ravasio. The minimum inhibitory concentration (MIC) was determined as the lowest concentration of compound that inhibited visible growth. A mirror reader was used to assist in determining the MIC endpoint.

- 30 One skilled in the art would consider any compound with a MIC of less than 64 µg/mL to be a potential lead compound. Preferably, the compounds used in the antimicrobial assays of the present invention have a MIC value of less than 16µg/mL.

Experimental and Examples

General

Proton nuclear magnetic resonance (^1H NMR) spectra were recorded at 300 MHz, and chemical shifts are reported in parts per million (δ) downfield from the internal standard tetramethylsilane (TMS). Abbreviations for NMR data are as follows: s = singlet, d = doublet, t = triplet, q = quartet, m = multiplet, dd = doublet of doublets, dt = doublet of triplets, app = apparent, br = broad. J indicates the NMR coupling constant measured in Hertz. CDCl_3 is deuteriochloroform, $\text{DMSO}-d_6$ is hexadeuteriodimethylsulfoxide, and CD_3OD is tetradeuteriomethanol. Mass spectra were obtained using electrospray (ES) ionization techniques. Elemental analyses were performed by Quantitative Technologies Inc., Whitehouse, NJ. Melting points were obtained on a Thomas-Hoover melting point apparatus and are uncorrected. All temperatures are reported in degrees Celsius. E. Merck Silica Gel 60 F-254 thin layer plates were used for thin layer chromatography. Flash chromatography was carried out on E. Merck Kieselgel 60 (230-400 mesh) silica gel. Analytical HPLC was performed on Beckman chromatography systems. Preparative HPLC was performed using Gilson chromatography systems. ODS refers to an octadecylsilyl derivatized silica gel chromatographic support. YMC ODS-AQ® is an ODS chromatographic support and is a registered trademark of YMC Co. Ltd., Kyoto, Japan. PRP-1® is a polymeric (styrene-divinylbenzene) chromatographic support, and is a registered trademark of Hamilton Co., Reno, Nevada. Celite® is a filter aid composed of acid-washed diatomaceous silica, and is a registered trademark of Manville Corp., Denver, Colorado.

Preparation 1

Preparation of [2-(4-bromophenyl)ethyl]carbamic acid *tert*-butyl ester

To a stirred solution of 4-bromophenethyl amine (5.0 g, 25.0 mmole) in dry THF (50 mL) at RT was added di-*tert*-butyl dicarbonate (5.45 g, 25.0 mmole) in dry THF (20 mL). After 30 min, the reaction contents were concentrated under reduced pressure to give the title compound (7.50 g, 99 %) as a white waxy solid: LC-MS (ES) m/e 301 ($M + H$) $^+$.

Preparation 2

Preparation of [2-(4-bromophenyl)methyl]carbamic acid *tert*-butyl ester

According to the procedure of Preparation 1, except substituting 4-bromobenzylamine hydrochloride (2.15 g, 9.66 mmole) for 4-bromophenethylamine, the title compound (2.73 g, 99 %) was prepared as an off-white solid following flash chromatography on silica gel (hexanes/EtOAc, 4:1): LC-MS (ES) m/e 287 (M + H)⁺.

Preparation 3

10 Preparation of 1,1,1-Trifluoromethanesulfonic acid 6-methoxy-[1,5]naphthyridin-4-yl ester

a) 4-Hydroxy-6-methoxy-[1,5]-naphthyridine

5-Amino-2-methoxypyridine (55.0 g, 0.44 mole) in methanol (1000 mL) with methyl propiolate (40 mL, 0.44 mole) was stirred for 48 hours, then evaporated and the product purified by chromatography on silica gel (dichloromethane) followed by recrystallization from dichloromethane-hexane (44.6 g, 48%). The unsaturated ester (10.5 g, 0.05 mole) in warm Dowtherm A (50 mL) was added over 3 minutes to refluxing Dowtherm A, and after a further 20 minutes at reflux the mixture was cooled and poured into diethyl ether. The precipitate was filtered to give a solid (6.26g, 70%).

20

b) 1,1,1-Trifluoromethanesulfonic acid 6-methoxy-[1,5]naphthyridin-4-yl ester

4-Hydroxy-6-methoxy-[1,5]naphthyridine (10g, 0.057 mole) in dichloromethane (200 mL) containing 2,6-lutidine (9.94 mL, 0.086 mole) and 4-dimethylaminopyridine (0.07 g, 0.0057 mole) was cooled in ice and treated with trifluoromethanesulfonic anhydride (10.5 mL, 0.063 mole). After stirring for 2.5 hours the mixture was washed with saturated ammonium chloride solution, dried, evaporated and purified on silica gel (dichloromethane) to give a light yellow solid (13.2 g, 75%). LC-MS (ES) m/e 309 (M+H)⁺.

30

Preparation 4

Preparation of 1,1,1-Trifluoro-methanesulfonic acid 8-fluoro-6-methoxyquinolin-4-yl ester

a) 8-Fluoro-6-methoxy-quinolin-4-ol

5 2-Fluoro-4-methoxyphenylamine (3.80g, 26.7 mmole) and methyl propiolate (2.37ml, 0.267 mole) in methanol (100ml) was stirred for 72 hours at room temperature, then heated at 50°C for 24 hours. It was evaporated and the product purified by chromatography on silica gel (dichloromethane) to give a solid (1.66g), a portion of which was recrystallised from dichloromethane-hexane. The
10 unsaturated ester (0.96g) in warm Dowtherm A (5ml) was added over 3 minutes to refluxing Dowtherm A (15ml), and after a further 20 minutes at reflux the mixture was cooled and poured into diethyl ether. The precipate was filtered to give the title compound (0.50 g, 61%). MS (ES) m/e 196 (M+H)⁺.

b) 1,1,1-Trifluoromethanesulfonic acid 8-fluoro-6-methoxy-quinolin-4-yl ester

15 8-Fluoro-6-methoxyquinolin-4-ol (0.48 g, 2.46 mmole) and dimethylaminopyridine (0.03 g) in dichloromethane (20 mL) and 2,6-lutidine (0.48 mL) was treated dropwise with triflic anhydride (0.48 ml) and the mixture was stirred at room temperature for 4 hours. It was washed with saturated ammonium chloride, dried, evaporated, and chromatographed on silica gel (dichloromethane)
20 to afford a yellow solid (0.69 g, 86%). MS (ES) m/e 326 (M+H)⁺.

Preparation 5

Preparation of 1,1,1-Trifluoromethanesulfonic acid 6,8-fluoro[1,5]naphthyridin-4-yl ester

25 According to the procedure of Preparation 4, except substituting 2,4-difluorophenylamine (12.9 g, 100 mmole) for 2-fluoro-4-methoxyphenylamine, the title compound (2.32 g, 8 %) was prepared as an off-white solid following flash chromatography on silica gel (EtOAc): LC-MS (ES) m/e 314 (M + H)⁺.

30

Preparation 6

Preparation of 4-bromo-6-methoxy quinoline

To a stirred solution of 4-hydroxy-6-methoxyquinoline (1.20 g, 70.5 mmole) in DMF (60 mL) at RT was added PBr₃ (8.0 mL, 84.6 mmole) dropwise. After 2h,

the reaction contents were poured onto H₂O (300 mL) and the product filtered and washed with H₂O to give, after drying under high vacuum, the title compound (14.3 g, 87%) as a light yellow solid: LC-MS (ES) m/e 233 (M+H)⁺.

5

Preparation 7

Preparation of {2-[4-(6-methoxy[1,5]naphthyridin-4-yl)phenyl]ethyl}carbamic acid *tert*-butyl ester

To a stirred solution of 1,1,1-trifluoromethanesulfonic acid 6-methoxy[1,5]naphthyridin-4-yl ester (1.0 g, 3.24 mmole) in dry dioxane (50 mL) at
10 RT was added bis(pinacolato)diboron (1.07 g, 4.22 mmole), potassium acetate (0.95 g, 9.72 mmole), 1,1-bis(diphenylphosphino)ferrocene (0.09 g, 0.16 mmole) and [1,1'-bis(diphenylphosphino)ferrocene]dichloropalladium(II) complexed with dichloromethane (1:1) (0.13 g, 0.16 mmole). The reaction contents were heated to 80 °C for 24h under nitrogen gas and then 1,1-bis(diphenylphosphino)ferrocene
15 (0.09 g, 0.16 mmole), [1,1'-bis(diphenylphosphino)ferrocene]dichloropalladium(II) complexed with dichloromethane (1:1) (0.13 g, 0.16 mmole), potassium carbonate (1.34 g, 9.72 mmole) and [2-(4-bromophenyl)ethyl]carbamic acid *tert*-butyl ester (0.97 g, 3.24 mmole) were added to the reaction pot. After 24h of vigorous stirring at 80 °C, the reaction contents were filtered through a scinter-glass funnel
20 containing a bed of celite (EtOAc). The filtrate was concentrated under vacuum and purified on silica (EtOAc) to afford the title compound (0.76 g, 62 %) as a tan solid: LC-MS (ES) m/e 380 (M + H)⁺.

Preparation 8

Preparation of {2-[4-(6-methoxy[1,5]naphthyridin-4-yl)phenyl]methyl}carbamic acid *tert*-butyl ester

According to the procedure of Preparation 7, except substituting [2-(4-bromophenyl)methyl]carbamic acid *tert*-butyl ester (1.71 g, 6.0 mmole) for [2-(4-bromophenyl)ethyl]carbamic acid *tert*-butyl ester, the title compound (1.38 g, 63 %)
30 was prepared as an off-white solid following flash chromatography on silica gel (EtOAc): MS (ES) m/e 366 (M + H)⁺.

Preparation 9

Preparation of {2-[4-(8-fluoro-6-methoxyquinolin-4-yl)phenyl]ethyl}carbamic acid *tert*-butyl ester

According to the procedure of Preparation 7, except substituting 1,1,1-trifluoromethanesulfonic acid 8-fluoro-6-methoxy[1,5]naphthyridin-4-yl ester (2.02 g, 4.48 mmole) for 1,1,1-trifluoromethanesulfonic acid 6-methoxy[1,5]naphthyridin-4-yl ester, the title compound (0.95 g, 53 %) was prepared as an off-white solid following flash chromatography on silica gel (EtOAc): LC-MS (ES) m/e 397 (M + H)⁺.

10

Preparation 10

Preparation of {2-[4-(6,8-difluoroquinolin-4-yl)phenyl]ethyl}carbamic acid *tert*-butyl ester

According to the procedure of Preparation 7, except substituting 1,1,1-trifluoromethanesulfonic acid 6,8-difluoro[1,5]naphthyridin-4-yl ester (2.11 g, 6.48 mmole) for 1,1,1-trifluoromethanesulfonic acid 6-methoxy[1,5]naphthyridin-4-yl ester, the title compound (1.25 g, 50 %) was prepared as an off-white solid following flash chromatography on silica gel (EtOAc): LC-MS (ES) m/e 385 (M + H)⁺.

20

Preparation 11

Preparation of {2-[4-(6-methoxyquinolin-4-yl)phenyl]ethyl}carbamic acid *tert*-butyl ester

According to the procedure of Preparation 7, except substituting 4-bromo-6-methoxyquinoline (1.26 g, 5.3 mmole) for 1,1,1-trifluoromethanesulfonic acid 6-methoxy[1,5]naphthyridin-4-yl ester, the title compound (1.33 g, 67 %) was prepared as an off-white solid following flash chromatography on silica gel (EtOAc): LC-MS (ES) m/e 379 (M + H)⁺.

30

Preparation 12

Preparation of 2-methoxy-8-(5-methylpyridin-2-yl)[1,5]naphthyridine

According to the procedure of Preparation 7, except substituting 2-bromo-5-methylpyridine (1.03 g, 6.0 mmole) for [2-(4-bromophenyl)ethyl]carbamic acid *tert*-butyl ester, the title compound (0.72 g, 48 %) was prepared as an off-white solid

following flash chromatography on silica gel (EtOAc): LC-MS (ES) m/e 252
($M + H$)⁺.

Preparation 13

5 Preparation of 2-methoxy-8-(6-methylpyridin-3-yl)[1,5]naphthyridine

According to the procedure of Preparation 7, except substituting 5-bromo-2-methylpyridine (1.11 g, 6.49 mmole) for [2-(4-bromophenyl)ethyl]carbamic acid *tert*-butyl ester, the title compound (0.81 g, 50%) was prepared as an off-white solid following flash chromatography on silica gel (EtOAc): LC-MS (ES) m/e 252

10 ($M + H$)⁺.

Preparation 14

Preparation of 3-Oxo-3,4-dihydro-2H-benzo[1,4]thiazine-6-carboxaldehyde

a) 3-Oxo-3,4-dihydro-2H-benzo[1,4]thiazine-6-carboxylic acid

15 3-Oxo-3,4-dihydro-2H-benzo[1,4]thiazine-6-carboxylic acid methyl ester (6.74 g) was suspended in tetrahydrofuran (100 mL) and 2M sodium hydroxide (30 mL) was added followed by water (20 mL). The solution was stirred for 2.5 hours, evaporated to half volume and acidified with 2M hydrochloric acid. The product was collected, washed with water and dried *in vacuo*, to give a white solid (6.2 g).

20 MS (-ve ion electrospray) m/e 208 ($M-H$)⁻.

b) 6-Hydroxymethyl-4H-benzo[1,4]thiazin-3-one

3-Oxo-3,4-dihydro-2H-benzo[1,4]thiazine-6-carboxylic acid in tetrahydrofuran (50 mL) and triethylamine (4.7 mL) was cooled to 0°C and *isobutylchloroformate* (4.02 mL) was added dropwise and the solution was stirred
25 at 0°C for 2 hours, when it was filtered into a stirred solution of sodium borohydride (3.14 g) in ice/water (50 mL). The mixture was stirred at 0°C for 1 hour and allowed to warm to room temperature. It was acidified with 2M hydrochloric acid, evaporated to half volume, and the resulting product was collected, washed with water and dried *in vacuo*, to give a white solid (4.5 g).

30 MS (-ve ion electrospray) m/e 194 ($M-H$)⁻.

c) 3-Oxo-3,4-dihydro-2H-benzo[1,4]thiazine-6-carbaldehyde

A stirred solution of 6-hydroxymethyl-4H-benzo[1,4]thiazin-3-one (3.5 g) in chloroform (150 mL) and tetrahydrofuran (300 mL) was treated with manganese

dioxide (7.8 g) for 18 hours and was filtered and evaporated to give a white solid (2.5 g).

MS (-ve ion electrospray) m/e 194 (M-H)⁻.

5

Preparation 15

Preparation of 3-Oxo-3,4-dihydro-2H-benzo[1,4]oxazine-6-carboxaldehyde

a) (4-Formyl-2-nitrophenoxy)acetic acid ethyl ester

A solution of 4-hydroxy-3-nitrobenzaldehyde (6.9 g) and ethyl bromoacetate (5.0 mL) in dimethylformamide (250 mL) was treated with anhydrous potassium carbonate (10 g) and the mixture was heated at 60°C for 18 hours and evaporated to dryness. The residue was partitioned between water and diethyl ether, and the diethyl ether layer was washed with 0.5M sodium hydroxide. It was then dried over anhydrous sodium sulfate and evaporated to give an oil that was chromatographed on silica gel (ethyl acetate/dichloromethane) to afford an oil (1.9 g). MS (+ve ion electrospray) m/e 253 (M + H)⁺.

b) 3-Oxo-3,4-dihydro-2H-benzo[1,4]oxazine-6-carboxaldehyde (4-Formyl-2-nitrophenoxy)acetic acid ethyl ester (1.9 g) in acetic acid (40 mL) was treated with iron powder (4.2 g) and the mixture was stirred at 60°C for 0.75 hours, filtered and evaporated to dryness. It was partitioned between aqueous sodium bicarbonate and ethyl acetate. The organic fraction was chromatographed on silica gel (ethyl acetate) to give a white solid (0.88 g). MS (-ve ion electrospray) m/e 176 (M-H)⁻.

Preparation 16

Preparation of 3-oxo-3,4-dihydro-2H-pyrido[3,2-b][1,4]thiazine-6-carboxaldehyde

a) Methyl 3-oxo-3,4-dihydro-2H-pyrido[3,2-b][1,4]thiazine-6-carboxylate

A solution of ethyl 2-mercaptoacetate (1.47 ml) in DMF (48 ml) was ice-cooled and treated with sodium hydride (540 mg of a 60% dispersion in oil). After 1 hour, methyl 6-amino-5-bromopyridine-2-carboxylate (3 g) (T.R. Kelly and F. Lang, *J. Org. Chem.* 61, 1996, 4623-4633) was added and the mixture stirred for 16 hours at room temperature. The solution was diluted with EtOAc (1 litre), washed with water (3 x 300 ml), dried and evaporated to about 10 ml. The white solid was filtered off and washed with a little EtOAc to give the ester (0.95g). MS (APCI⁻) m/e 223 ([M-H]⁻, 100%).

b) 3-Oxo-3,4-dihydro-2*H*-pyrido[3,2-*b*][1,4]thiazine-6-carboxylic acid

A solution of Methyl 3-oxo-3,4-dihydro-2*H*-pyrido[3,2-*b*][1,4]thiazine-6-carboxylate (788 mg) in dioxane (120 ml)/water (30 ml) was treated dropwise over 2 hours with 0.5M NaOH solution (8 ml) and stirred overnight. After evaporation to approx. 3 ml, water (5ml) was added and 2N HCl to pH = 4. The precipitated solid was filtered off, washed with a small volume of water and dried under vacuum to give a solid (636mg). MS (APCI⁻) m/e 209 ([M-H]⁻, 5%), 165([M-COOH]⁻, 100%).

c) 6-Hydroxymethyl-3-oxo-3,4-dihydro-2*H*-pyrido[3,2-*b*][1,4]thiazine

A solution of 3-Oxo-3,4-dihydro-2*H*-pyrido[3,2-*b*][1,4]thiazine-6-carboxylic acid (500 mg) in THF (24 mL) with triethylamine (0.4 mL) was cooled to -10°C and isobutyl chloroformate (0.339 mL) added. After 20 minutes the suspension was filtered through celite into an ice-cooled solution of sodium borohydride (272 mg) in water (8 ml), the mixture stirred 30 minutes and the pH reduced to 7 with dilute HCl. The solvent was evaporated and the residue triturated under water. The product was filtered and dried under vacuum to give a white solid (346mg). MS (APCI⁻) m/e 195 ([M-H]⁻, 50%), 165(100%).

d) 3-Oxo-3,4-dihydro-2*H*-pyrido[3,2-*b*][1,4]thiazine-6-carboxaldehyde

A solution of 6-Hydroxymethyl-3-oxo-3,4-dihydro-2*H*-pyrido[3,2-*b*][1,4]thiazine (330 mg) in dichloromethane (30 ml)/THF (30 ml) was treated with manganese dioxide (730 mg) and stirred at room temperature. Further manganese dioxide was added after 1 hour (730 mg) and 16 hours (300 mg). After a total of 20 hours the mixture was filtered through celite and the filtrate evaporated. The product was triturated with EtOAc/hexane (1:1) and collected to give a solid (180mg). MS (APCI⁻) m/e 195 ([M-H]⁻, 95%), 165 (100%).

Preparation 1730 Preparation of 3-Oxo-3,4-dihydro-2*H*-pyrido[3,2-*b*][1,4]oxazine-6-carboxaldehyde

a) 5-Bromo-3-hydroxy-2-nitropyridine

N-bromosuccinimide (165 g, 0.927 mole) was added portionwise over 5 h to a solution of 3-hydroxy-2-nitropyridine (100.0 g, 0.714 mole) in DMF (1 L) at 0 °C. The resulting mixture was stirred at room temperature for 15 hr then was

concentrated *in vacuo*. The residue was taken up in Et₂O (500 mL) and stirred for 30 min. The precipitate was removed by suction filtration, and the filtrate was concentrated *in vacuo* to afford the title compound (180 g): MS (ES) m/e 219 (M + H)⁺. This material was used without further purification.

5

b) Ethyl (6-bromo-2-nitropyridin-3-yloxy)acetate

5-Bromo-3-hydroxy-2-nitropyridine (40 g of crude material from previous reaction, 0.14 mole) was suspended in acetone (650 mL) with mechanical stirring, and K₂CO₃ (39 g, 0.28 mole) was added, followed by ethyl bromoacetate (19 mL, 0.171 mmole). The reaction was heated at reflux for 10 hr, then was cooled to room temperature and diluted with H₂O (1 L). The mixture was extracted with Et₂O (2 x 700 mL), and the combined organic layers were washed sequentially with H₂O and brine, dried (Na₂SO₄), and concentrated *in vacuo* to afford the title compound (41 g): LC-MS (ES) m/e 305 (M + H)⁺. This material was >85% pure and used without further purification.

15

c) 6-Bromo-4*H*-pyrido[3,2-*b*][1,4]oxazin-3-one

Ethyl (6-bromo-2-nitropyridin-3-yloxy)acetate (41 g, 0.132 mole) was dissolved in glacial AcOH (400 mL) and the solution was heated to 77 °C with mechanical stirring. Iron powder (50 g, 0.89 mole) was added portionwise over 2 hr, so that the temperature did not rise above 90°C. The mixture was mechanically stirred and heated at 77 °C for 10 hr then was cooled to room temperature and diluted with 1:4 EtOAc/CHCl₃ (1 L). The mixture was filtered through a pad of celite® and the filtrate was concentrated *in vacuo*. The residue was purified by flash chromatography on silica gel (1 kg; 0-10% EtOAc/CHCl₃) to afford the title compound (21.5 g, 70%): MS (ES) m/e 229 (M + H)⁺.

25

d) 6-((*E*)-Styryl)-4*H*-pyrido[3,2-*b*][1,4]oxazin-3-one

6-Bromo-4*H*-pyrido[3,2-*b*][1,4]oxazin-3-one (10.0 g, 44 mmole) and *trans*-2-phenylvinylboronic acid (9.0 g, 61 mmole) were dissolved in 1,4-dioxane (200 mL) and the solution was degassed with argon. (Ph₃P)₄Pd (2.5 g, 2.2 mmole) was added, followed by a solution of K₂CO₃ (15 g, 109 mmole) in H₂O (100 mL). The

30

reaction was heated at reflux under argon overnight, then was cooled to room temperature and diluted with chloroform (400 mL). The solution was washed sequentially with H₂O and brine, dried (Na₂SO₄), and concentrated *in vacuo*. The solid residue was recrystallized from hot EtOAc to afford the title compound (6.4 g, 57.5%): LC-MS (ES) m/e 253 (M + H)⁺.

e) 3-Oxo-3,4-dihydro-2*H*-pyrido[3,2-*b*][1,4]oxazine-6-carboxaldehyde

6-((*E*-Styryl)-4*H*-pyrido[3,2-*b*][1,4]oxazin-3-one (6.2 g, 27 mmole) was dissolved in 5:1 CH₂Cl₂/MeOH (500 mL) and the solution was cooled to -78 °C.

Ozone was bubbled through the solution with stirring until a pale blue color appeared, then the excess ozone was removed by bubbling oxygen through the solution for 15 min. Dimethylsulfide (9.9 mL, 135 mmole) was added to the solution, and the reaction was stirred at -78 °C for 3 hr, then at room temperature overnight. The solvent was removed *in vacuo*, and the residue was triturated and stirred with Et₂O (150 mL). The solid was collected by suction filtration, washed with additional Et₂O, and dried to afford the title compound (3.4 g, 77%): LC-MS (ES) m/e 179 (M + H)⁺.

Preparation 18

20 Preparation of 3-oxo-3,4-dihydro-2*H*-benzo[1,4]thiazine-6-sulfonyl chloride

Powdered 4*H*-benzo[1,4]thiazin-3-one (7.0g) was added cautiously, portionwise (over 20 minutes), to chlorosulfonic acid (15 mL), cooled in ice. After 1 hour, the blue solution was allowed to warm to room temperature and it was heated at 45°C for 2 hours, cooled and poured into ice. The solid was collected, washed with water, and hexane, and dried *in vacuo*, to give a white solid (7.0 g): LC-MS (ES) m/e 263 (M)⁺.

Preparation 19

Preparation of 2-Oxo-2,3-dihydro-1*H*-pyrido[2,3-*b*][1,4]thiazine-7-carboxaldehyde

30 a) 6-Methoxycarbonylmethylsulfanyl-5-nitro-nicotinic acid methyl ester

A solution of 6-chloro-5-nitronicotinic acid methyl ester (1.0 g) [prepared as described by A.H. Berrie *et al.* *J. Chem. Soc.* 2590 –2594 (1951)] in dichloromethane (10 mL) containing triethylamine (0.76 mL) was treated with

mercapto-acetic acid methyl ester (0.44 mL) and the solution was stirred at room temperature for 1 hour and evaporated to dryness. Sodium bicarbonate solution was added and the mixture was extracted with dichloromethane, dried (anhydrous sodium sulfate) and evaporated to afford a solid (1.0 g). MS (ES) m/e 287 (M+H)⁺.

5

b) 2-Oxo-2,3-dihydro-1*H*-pyrido[2,3-*b*][1,4]thiazine-7-carboxylic acid methyl ester
6-Methoxycarbonylmethylsulfanyl-5-nitro-nicotinic acid methyl ester (1.0 g)

in acetic acid (50mL) was treated with iron powder (10 g) and the mixture was stirred and heated at 60°C for 1 hour, cooled and filtered. The filtrate was
10 evaporated, treated with sodium bicarbonate solution and extracted with warm chloroform. It was dried (anhydrous sodium sulfate) and evaporated to give a white solid (0.85g).

MS (ES) m/e 225 (M+H)⁺.

15 c) 2-Oxo-2,3-dihydro-1*H*-pyrido[2,3-*b*][1,4]thiazine-7-carboxylic acid

2-Oxo-2,3-dihydro-1*H*-pyrido[2,3-*b*][1,4]thiazine-7-carboxylic acid methyl ester (2.8 g) was hydrolyzed with aqueous sodium hydroxide in tetrahydrofuran by the method of Preparation (14a) to afford a solid (2.5 g). MS (-ve ion electrospray) m/e 209 (M-H⁻).

20

d) 7-Hydroxymethyl-1*H*-pyrido[2,3-*b*][1,4]thiazin-2-one

2-Oxo-2,3-dihydro-1*H*-pyrido[2,3-*b*][1,4]thiazine-7-carboxylic acid (2.48 g) was reacted with *iso*-butylchloroformate and sodium borohydride by the method of Preparation (14b) to afford a solid (1.3 g), after recrystallisation from chloroform-
25 methanol (9:1). MS (ES) m/e 197 (M+H)⁺.

e) 2-Oxo-2,3-dihydro-1*H*-pyrido[2,3-*b*][1,4]thiazine-7-carboxaldehyde

7-Hydroxymethyl-1*H*-pyrido[2,3-*b*][1,4]thiazin-2-one (1.22 g) was oxidized with manganese dioxide by the method of Preparation (14c) to afford a solid (0.7
30 g).
MS (-ve ion electrospray) m/e 193 (M-H⁻).

Preparation 20

Preparation of 7-fluoro-2,3-dihydrobenzo[1,4]dioxine-6-carboxaldehyde

7-Fluoro-2,3-dihydrobenzo[1,4]dioxine-6-carboxaldehyde was prepared from 6-fluoro-2,3-dihydrobenzo[1,4]dioxine [V. Daukas et al Chemija, 1999, 10 (1), 59] by reaction of dichloromethyl methyl ether and titanium tetrachloride: LC-MS (ES) m/e 155 (M+H)⁺.

Preparation 21

Preparation of 6-(2-Chloroethyl)-4H-benzof[1,4]oxazin-3-one

10

To a dried flask under N₂ atmosphere equipped with addition funnel was added 6-(2-chloroethanoyl)-4H-benzo[1,4]oxazin-3-one (10.0 g, 44.4 mmol) in trifluoroacetic acid (34 mL, 0.44 mol). To the resulting mixture at 0° C was added triethylsilane (15.3 mL, 0.1 mole) dropwise over 5 min. The resulting mixture was warmed to 45° C for 30 min and stirred at room temperature for 40 h. Reaction was poured onto ice water and layered with EtOAc. The organic layer was washed with water, brine, and dried over MgSO₄. Solvent was removed on vacuum to give the desired compound as white solid (9.0 g, 93%). LC-MS (ES): m/e 212 (M+H)⁺.

20

Preparation 22

Preparation of toluene-4-sulfonic acid 2-(3-oxo-3,4-dihydro-2H-benzo[1,4]thiazin-6-yl)ethyl ester

a) 6-Vinyl-4H-benzo[1,4]thiazin-3-one

To a stirred suspension of triphenylmethylphosphonium bromide (20.0 mmole) in dry THF (40 mL) at RT was added 2.5 M n-BuLi (7.5 mL, 3.0 mmole). After 3h, 3-oxo-3,4-dihydro-2H-benzo[1,4]thiazine-6-carboxaldehyde (1.93 g, 10.0 mmole) was added and the reaction contents were stirred at RT overnight. The reaction solution was filtered and the filtrate concentrated, dissolved in EtOAc and washed with 1M HCl (20mL). The organic solution was dried (Na₂SO₄) and concentrated under vacuum. Purification on silica (EtOAc/hexanes, 1:4) afforded the title compound (1.20 g, 63%) as light yellow solid: LC-MS (ES): m/e 192 (M+H)⁺.

b) 6-(2-Hydroxyethyl) 4H-benzo[1,4]thiazin-3-one

To a stirred solution of 6-vinyl-4H-benzo[1,4]thiazin-3-one (5.73 g, 30.0 mmole) in dry THF (100 mL) at RT was added 2M BH₃·THF (7.5 mL, 15.0 mmole). After 24h, H₂O (15 mL) was slowly added to the reaction mixture followed by 3M NaOH (5 mL) and 30% H₂O₂ (3.3 mL). After the reaction solution was stirred for 3h at 50 °C, the reaction was concentrated under vacuum. The residue was dissolved in EtOAc and washed with H₂O (20 mL) and 1M HCl (20mL). The organic solution was dried (Na₂SO₄), concentrated under vacuum, and the remaining solid purified on silica (CH₂Cl₂/CH₃OH, 95:5) afforded the title compound (2.60 g, 41%) as light yellow solid: LC-MS (ES): m/e 210 (M+H)⁺.

c) Toluene-4-sulfonic acid 2-(3-oxo-3,4-dihydro-2H-benzo[1,4]thiazin-6-yl)ethyl ester

To a stirred solution of 6-(2-hydroxyethyl) 4H-benzo[1,4]thiazin-3-one (2.09 g, 10.0 mmole) in dry pyridine (25 mL) at RT was added p-toluenesulfonyl chloride (10.0 mmole). After 24h, the reaction solution was concentrated under vacuum. Purification on silica (EtOAc/hexanes, 1:1) afforded the title compound (0.91 g, 47%) as light yellow solid: LC-MS (ES): m/e 192 (M+H)⁺.

20

Preparation 23Preparation of 1,1-dimethylethyl [2-(5-bromo-2-pyridinyl)ethyl]carbamate

a) 5-bromo-2-(bromomethyl)pyridine

To a stirred solution of 5-bromo-2-methylpyridine (1.2 g, 4.78 mmole), in dry CCl₄ (150 mL) at RT was added NBS (1.02 g, 5.73 mmole) and benzoylperoxide (0.12 g, 0.48 mmole). After 18h at reflux, the reaction contents were cooled to RT and filtered through a scintered-glass funnel washing with CHCl₃. Concentration under vacuum and purification on silica (EtOAc) afforded the title compound (1.12 g, 71%) as light yellow solid: (EtOAc): LC-MS (ES) m/e 330 (M)⁺.

30

b) (5-bromo-2-pyridinyl)acetonitrile

To a stirred solution of 5-bromo-2-(bromomethyl)pyridine (0.70 g, 2.12 mmole), in EtOH (50 mL) at 60 °C was added KCN (0.21 g, 3.18 mmole) in H₂O (3

mL). After 1.5h, the reaction contents were cooled to RT and concentrated under vacuum. The aqueous residue was dissolved in EtOAc and washed with H₂O, and dried over Na₂SO₄. Concentration under vacuum and purification on silica (EtOAc) afforded the title compound (0.38 g, 65%) as light yellow solid: LC-MS (ES) m/e 277 (M + H)⁺.

c) [2-(5-bromo-2-pyridinyl)ethyl]amine

To a stirred solution of (5-bromo-2-pyridinyl)acetonitrile (0.26 g, 0.94 mmole), in THF (20 mL) at RT was added 1M BH₃·THF (5 mL, 5.0 mmole). After 24h, H₂O (10 mL) wash added dropwise to the reaction solution followed by 1M HCl (10 mL). After 1h, the reaction solution was made basic by addition of 6M NaOH (2 mL). The reaction contents were concentrated under vacuum and extracted with EtOAc (3 x 50 mL). The organic phase was dried over Na₂SO₄ and concentrated under vacuum affording the crude title compound as light orange solid which was used directly without further purification: LC-MS (ES) m/e 281 (M + H)⁺.

(d) 1,1-dimethylethyl [2-(5-bromo-2-pyridinyl)ethyl]carbamate

To a stirred solution of [2-(5-bromo-2-pyridinyl)ethyl]amine (5.0 g, 25.0 mmole) in dry THF (50 mL) at RT was added di-*tert*-butyl dicarbonate (5.45 g, 25.0 mmole) in dry THF (20 mL). After 30 min, the reaction contents were concentrated under reduced pressure to give the title compound (7.50 g, 99 %) as a white waxy solid: LC-MS (ES) m/e 301 (M + H)⁺.

25

Preparation 24

Preparation of 1,1-dimethylethyl [2-(6-chloro-3-pyridinyl)ethyl]carbamate

According to the procedure of Preparation 1, except substituting 2-chloro-5-methylpyridine (1.71 g, 6.0 mmole) for 5-bromo-2-methylpyridine, the title compound (1.38 g, 63 %) was prepared as an off-white solid following flash chromatography on silica gel (EtOAc): MS (ES) m/e 366 (M + H)⁺.

30

Example 1Preparation of 6-((2-[4-(6-Methoxy-[1,5]naphthyridin-4-yl)phenyl]ethylamino)methyl)-4*H*-benzo[1,4]thiazin-3-one

a) 2-[4-(6-Methoxy-[1,5]naphthyridin-4-yl)phenyl]ethylamine hydrochloride salt

5 To a stirred solution of {2-[4-(6-methoxy[1,5]naphthyridin-4-yl)phenyl]ethyl}carbamic acid *tert*-butyl ester (0.67 g, 1.76 mmole) in dry CH₂Cl₂ (75 mL) at RT was added trifluoroacetic acid (50 mL). After 2 h, the reaction solution was concentrated under vacuum and the residue dissolved in 4M HCl in dioxane (5 mL) at RT. After 1 hr, the reaction contents were concentrated and dried
10 under high vacuum to give the crude title compound as a tan solid which was used immediately in the proceeding reaction: LC-MS (ES) m/e 280 (M + H)⁺.

b) 6-((2-[4-(6-Methoxy-[1,5]naphthyridin-4-yl)phenyl]ethylamino)methyl)-4*H*-benzo[1,4]thiazin-3-one

15 To a stirred solution of 2-[4-(6-Methoxy-[1,5]naphthyridin-4-yl)phenyl]ethylamine hydrochloride salt (1.76 mmole) in dry CH₂Cl₂ (25 mL) and dry EtOH (10 mL) at RT was added triethylamine (0.74 mL, 5.28 mmole) and 3-oxo-3,4-dihydro-2*H*-benzo[1,4]thiazine-6-carboxaldehyde (0.34 g, 1.76 mmole). After 24h, the reaction contents were concentrated and dried under high vacuum.
20 To a stirred solution of the crude imine in dry EtOH (25 mL) at RT was added NaBH₄ (0.66 g, 1.76 mmole). After 24h, the reaction solution was concentrated under vacuum and to the residue was added 1M HCl (5mL) and EtOAc (50 mL). After stirring for 1h, 6M NaOH (1mL) was added and the organic layer was separated, dried (Na₂SO₄) and concentrated. Purification on silica (CHCl₃/MeOH,
25 9:1 containing 5% NH₄OH) afforded the title compound (0.55 g, 69%) as light yellow solid: ¹H NMR (400 MHz, CD₃OD) δ 9.11 (d, *J* = 4.5 Hz, 1H), 8.57 (d, *J* = 9.1 Hz, 1H), 8.27 (d, *J* = 4.5 Hz, 1H), 8.14 (m, 2H), 7.90 (s, 2H), 7.61 (m, 3H), 7.46 (d, *J* = 7.1 Hz, 1H), 7.22 (m, 2H), 5.52 (m, 2H), 4.23 (s, 2H), 4.08 (s, 3H), 3.68 (s, 2H), 3.19 (m, 2H). LC-MS (ES) m/e 457 (M + H)⁺.

30

Example 2

Preparation of 6-({2-[4-(6-Methoxy-[1,5]naphthyridin-4-yl)phenyl]ethylamino)methyl}-4H-pyrido[3,2-b][1,4]thiazin-3-one

According to the procedure of Example 1, except substituting 3-oxo-3,4-dihydro-2H-pyrido[2,3-b][1,4]thiazine-6-carboxaldehyde (0.15 g, 0.76 mmole) for 3-oxo-3,4-dihydro-2H-benzo[1,4]thiazine-6-carboxaldehyde, the title compound (0.21 g, 61 %) was prepared as an off-white solid following flash chromatography on silica gel (CHCl₃/MeOH, 9:1, containing 5% NH₄OH): ¹H NMR (400 MHz, CDCl₃) δ 8.72 (d, *J* = 4.5 Hz, 1H), 8.20 (d, *J* = 9.0 Hz, 1H), 7.71 (d, *J* = 8.1 Hz, 2H), 7.47 (m, 2H), 7.23 (m, 2H), 7.03 (d, *J* = 9.0 Hz, 1H), 6.86 (d, *J* = 7.9 Hz, 1H), 3.86 (s, 3H), 3.80 (s, 2H), 3.35 (s, 2H), 2.86 (m, 4H). LC-MS (ES) *m/e* 458 (M + H)⁺.

Example 3

Preparation of 6-({2-[4-(6-Methoxyquinolin-4-yl)phenyl]ethylamino)methyl}-4H-pyrido[3,2-b][1,4]oxazin-3-one

According to the procedure of Example 1, except substituting {2-[4-(6-methoxyquinolin-4-yl)phenyl]ethyl}carbamic acid *tert*-butyl ester (0.31 g, 0.82 mmole) for {2-[4-(6-methoxy[1,5]naphthyridin-4-yl)phenyl]ethyl}carbamic acid *tert*-butyl ester, and substituting 2-oxo-2,3-dihydro-1H-pyrido[2,3-b][1,4]thiazine-7-carboxaldehyde (0.18 g, 0.9 mmole) for 3-oxo-3,4-dihydro-2H-benzo[1,4]thiazine-6-carboxaldehyde, the title compound (0.14 g, 37 %) was prepared as an off-white solid following flash chromatography on silica gel (CHCl₃/MeOH, 9:1, containing 5% NH₄OH): ¹H NMR (400 MHz, d₆-DMSO) δ 10.89 (br s, 1H), 8.77 (d, *J* = 4.5 Hz, 1H), 8.02 (d, *J* = 9.1 Hz, 1H), 7.73 (d, *J* = 7.8 Hz, 1H), 7.52 (d, *J* = 8.0 Hz, 1H), 7.46 (m, 1H), 7.38 (d, *J* = 4.4 Hz, 1H), 7.22 (d, *J* = 2.8 Hz, 1H), 7.07 (d, *J* = 7.9 Hz, 1H), 3.76 (s, 3H), 3.53 (s, 2H), 3.38 (m, 2H), 3.20 (m, 2H), 2.86 (m, 2H). LC-MS (ES) *m/e* 457 (M + H)⁺.

Example 4

Preparation of 7-({2-[4-(6-Methoxy-[1,5]naphthyridin-4-yl)phenyl]ethylamino)methyl}-1H-pyrido[3,2-b][1,4]thiazin-2-one

According to the procedure of Example 1, except substituting 3-oxo-3,4-dihydro-2H-pyrido[3,2-b][1,4]thiazine-6-carboxaldehyde (0.14 g, 0.70 mmole) for 3-

oxo-3,4-dihydro-2*H*-benzo[1,4]thiazine-6-carboxaldehyde, the title compound (0.17 g, 58 %) was prepared as an off-white solid following flash chromatography on silica gel (CHCl₃/MeOH, 9:1, containing 5% NH₄OH): ¹H NMR (400 MHz, d₆-DMSO) δ 10.63 (br s, 1H), 8.83 (d, *J* = 4.5 Hz, 1H), 8.32 (d, *J* = 9.1 Hz, 1H), 8.05 (s, 1H), 7.87 (d, *J* = 7.8 Hz, 2H), 7.72 (d, *J* = 4.6 Hz, 1H), 7.38 (m, 2H), 7.26 (m, 2H), 3.92 (s, 3H), 3.71 (s, 2H), 3.63 (s, 2H), 2.81 (m, 4H). LC-MS (ES) *m/e* 458 (M + H)⁺.

Example 5

10 Preparation of 6-({2-[4-(6-Methoxy-[1,5]naphthyridin-4-yl)phenyl]ethylamino}methyl)-4*H*-pyrido[3,2-*b*][1,4]oxazin-3-one

According to the procedure of Example 1, except substituting 3-oxo-3,4-dihydro-2*H*-pyrido[3,2-*b*][1,4]oxazine-6-carboxaldehyde (0.13 g, 0.76 mmole) for 3-oxo-3,4-dihydro-2*H*-benzo[1,4]thiazine-6-carboxaldehyde, the title compound (0.20 g, 60 %) was prepared as an off-white solid following flash chromatography on silica gel (CHCl₃/MeOH, 9:1, containing 5% NH₄OH): ¹H NMR (400 MHz, CDCl₃) δ 8.74 (d, *J* = 4.5 Hz, 1H), 8.21 (d, *J* = 9.0 Hz, 1H), 7.70 (d, *J* = 8.1 Hz, 2H), 7.44 (d, *J* = 4.6 Hz, 1H), 7.25 (m, 2H), 7.08 (m, 2H), 6.83 (d, *J* = 8.1 Hz, 1H), 4.52 (s, 2H), 3.86 (s, 3H), 3.80 (s, 2H), 2.86 (m, 4H). LC-MS (ES) *m/e* 442 (M + H)⁺.

20

Example 6

Preparation of 3-Oxo-3,4-dihydro-2*H*-benzo[1,4]thiazine-6-sulfonic acid {2-[4-(6-methoxy-[1,5]naphthyridin-4-yl)phenyl]ethyl}amide

To a stirred solution of 2-[4-(6-Methoxy-[1,5]naphthyridin-4-yl)phenyl]ethylamine hydrochloride salt (0.10 g, 0.26 mmole), from Example 1a, in dry CH₂Cl₂ (25 mL) at RT was added triethylamine (0.11 mL, 0.78 mmole) and 3-oxo-3,4-dihydro-2*H*-benzo[1,4]thiazine-6-sulfonyl chloride (69 mg, 0.26 mmole). After 24h, the reaction contents were concentrated. Purification on silica (CHCl₃/MeOH, 9:1 containing 5% NH₄OH) afforded the title compound (0.10 g, 75%) as light yellow solid: ¹H NMR (400 MHz, CD₃OD) δ 9.06 (d, *J* = 4.5 Hz, 1H), 8.57 (d, *J* = 9.0 Hz, 1H), 8.26 (d, *J* = 4.6 Hz, 1H), 8.10 (d, *J* = 9.1 Hz, 2H), 7.73 (m, 3H), 7.45 (d, *J* = 9.0, 1H), 7.17 (m, 2H), 4.25 (s, 2H), 4.06 (s, 3H), 3.77 (m, 2H), 3.31 (m, 2H). LC-MS (ES) *m/e* 507 (M + H)⁺.

30

Example 7

Preparation of {2-[4-(6-Methoxy-[1,5]naphthyridin-4-yl)phenyl]ethyl} (5,6,7,8-tetrahydro[1,8]naphthyridin-2-ylmethyl)amine

5 According to the procedure of Example 1, except substituting 5,6,7,8-tetrahydro [1,8]naphthyridine-2-carboxaldehyde [Merck Patent WO 98/08840] (0.16 g, 1.0 mmole) for 3-oxo-3,4-dihydro-2*H*-benzo[1,4]thiazine-6-carboxaldehyde, the title compound (0.26 g, 62 %) was prepared as an off-white solid following flash chromatography on silica gel (CHCl₃/MeOH, 9:1, containing 5% NH₄OH): ¹H NMR
10 (400 MHz, CDCl₃) δ 8.81 (d, *J* = 4.5 Hz, 1H), 8.25 (d, *J* = 9.0 Hz, 1H), 7.83 (d, *J* = 8.2 Hz, 2H), 7.59 (d, *J* = 4.5 Hz, 1H), 7.36 (d, *J* = 8.1 Hz, 1H), 7.15 (d, *J* = 9.0 Hz, 1H), 7.09 (d, *J* = 7.3 Hz, 1H), 6.47 (d, *J* = 7.3 Hz, 1H), 4.79 (br s, 1H), 4.00 (s, 3H), 3.73 (s, 2H), 3.36 (m, 2H), 2.97 (m, 4H), 2.71 (m, 2H), 1.91 (m, 2H). LC-MS (ES) *m/e* 426 (M + H)⁺.

15

Example 8

Preparation of 6-{2-[4-(6-Methoxy-[1,5]naphthyridin-4-yl)benzylamino]ethyl}-4*H*-benzo[1,4]oxazin-3-one

a) 2-[4-(6-methoxy-[1,5]naphthyridin-4-yl)phenyl]methylamine trihydrochloride salt
20 According to the procedure of Example 1a, except substituting 2-[4-(6-methoxy[1,5]naphthyridin-4-yl)phenyl]methyl carbamic acid *tert*-butyl ester (2.33 g, 6.38 mmole) for {2-[4-(6-methoxy[1,5]naphthyridin-4-yl)phenyl]methyl}carbamic acid *tert*-butyl ester, the crude title compound (2.35 g, 99 %) was prepared as an off-white solid: LC-MS (ES) *m/e* 266 (M + H)⁺.

25

b) 6-{2-[4-(6-Methoxy-[1,5]naphthyridin-4-yl)benzylamino]ethyl}-4*H*-benzo[1,4]oxazin-3-one

To a stirred solution of 2-[4-(6-methoxy-[1,5]naphthyridin-4-yl)phenyl]methylamine trihydrochloride salt (0.42 g, 1.14 mmole), from Example 8a,
30 in dry acetonitrile (50 mL) at RT was added K₂CO₃ (0.79 g, 5.70 mmole), KI (cat.) and 6-(2-chloroethyl)-4*H*-benzo[1,4]oxazin-3-one (0.24 g, 1.14 mmole). After 72h at reflux, the reaction contents were cooled to RT and concentrated. Purification on silica (CHCl₃/MeOH, 9:1 containing 5% NH₄OH) afforded the title compound (0.20

g, 40%) as light yellow solid: (CHCl₃/MeOH, 9:1, containing 5% NH₄OH): ¹H NMR (400 MHz, CDCl₃) δ 8.81 (d, *J* = 4.5 Hz, 1H), 8.28 (d, *J* = 9.0 Hz, 1H), 7.85 (d, *J* = 8.1 Hz, 2H), 7.57 (d, *J* = 4.6 Hz, 1H), 7.44 (m, 2H), 7.14 (d, *J* = 9.0, 1H), 6.83 (m, 2H), 6.63 (s, 1H), 4.59 (s, 2H), 3.96 (s, 3H), 3.92 (s, 2H), 2.97 (m, 2H), 2.79 (m, 2H). LC-MS (ES) *m/e* 441 (M + H)⁺.

Example 9

Preparation of 6-{2-[4-(6-Methoxy-[1,5]naphthyridin-4-yl)benzylamino]ethyl}-4*H*-benzo[1,4]thiazin-3-one

According to the procedure of Example 8, except substituting toluene-4-sulfonic acid 2-(3-oxo-3,4-dihydro-2*H*-benzo[1,4]thiazin-6-yl)ethyl ester (0.16 g, 0.44 mmole) for 6-(2-chloroethyl)-4*H*-benzo[1,4]oxazin-3-one, the crude title compound (84 mg, 42 %) was prepared as an off-white solid: ¹H NMR (400 MHz, CDCl₃) δ 9.16 (br s, 1H), 8.84 (d, *J* = 4.5 Hz, 1H), 8.27 (d, *J* = 9.0 Hz, 1H), 7.86 (d, *J* = 8.1 Hz, 2H), 7.58 (d, *J* = 4.6 Hz, 1H), 7.44 (d, *J* = 8.2 Hz, 2H), 7.23 (d, *J* = 7.9 Hz, 1H), 7.16 (d, *J* = 9.0, 1H), 6.93 (m, 1H), 6.76 (s, 1H), 3.96 (s, 3H), 3.92 (s, 2H), 3.42 (s, 2H), 2.97 (m, 2H), 2.83 (m, 2H). LC-MS (ES) *m/e* 457 (M + H)⁺.

Example 10

Preparation of 6-({2-[6-(6-methoxy-[1,5]naphthyridin-4-yl)pyridin-3-yl]ethylamino)methyl}-4*H*-pyrido[3,2-*b*][1,4]thiazin-3-one

a) 8-(5-bromomethylpyridin-2-yl)-2-methoxy[1,5]naphthyridine

To a stirred solution of 2-methoxy-8-(5-methylpyridin-2-yl)[1,5]naphthyridine (1.2 g, 4.78 mmole), in dry CCl₄ (150 mL) at RT was added NBS (1.02 g, 5.73 mmole) and benzoylperoxide (0.12 g, 0.48 mmole). After 18h at reflux, the reaction contents were cooled to RT and filtered through a scintered-glass funnel washing with CHCl₃. Concentration under vacuum and purification on silica (EtOAc) afforded the title compound (1.12 g, 71%) as light yellow solid: (EtOAc): LC-MS (ES) *m/e* 330 (M)⁺.

b) [6-(6-methoxy[1,5]naphthyridin-4-yl)pyridin-3-yl]acetonitrile

To a stirred solution of 8-(5-bromomethylpyridin-2-yl)-2-methoxy[1,5]naphthyridine (0.70 g, 2.12 mmole), in EtOH (50 mL) at 60 °C was added KCN (0.21 g, 3.18 mmole) in H₂O (3 mL). After 1.5h, the reaction contents were cooled to RT and concentrated under vacuum. The aqueous residue was dissolved in EtOAc and washed with H₂O, and dried over Na₂SO₄. Concentration under vacuum and purification on silica (EtOAc) afforded the title compound (0.38 g, 65%) as light yellow solid: LC-MS (ES) m/e 277 (M + H)⁺.

c) 2-[6-(6-methoxy[1,5]naphthyridin-4-yl)pyridin-3-yl]ethylamine

To a stirred solution of [6-(6-methoxy[1,5]naphthyridin-4-yl)pyridin-3-yl]acetonitrile (0.26 g, 0.94 mmole), in THF (20 mL) at RT was added 1M BH₃-THF (5 mL, 5.0 mmole). After 24h, H₂O (10 mL) wash added dropwise to the reaction solution followed by 1M HCl (10 mL). After 1h, the reaction solution was made basic by addition of 6M NaOH (2 mL). The reaction contents were concentrated under vacuum and extracted with EtOAc (3 x 50 mL). The organic phase was dried over Na₂SO₄ and concentrated under vacuum affording the crude title compound as light orange solid which was used directly without further purification: LC-MS (ES) m/e 281 (M + H)⁺.

d) 6-((2-[6-(6-methoxy-[1,5]naphthyridin-4-yl)pyridin-3-yl]ethylamino)methyl)-4H-pyrido[3,2-b][1,4]thiazin-3-one

To a stirred solution of 2-[6-(6-methoxy[1,5]naphthyridin-4-yl)pyridin-3-yl]ethylamine (0.94 mmole) in dry CH₂Cl₂ (25 mL) and dry EtOH (10 mL) at RT was added 3-oxo-3,4-dihydro-2H-pyrido[3,2-b][1,4]thiazine-6-carboxaldehyde (0.18 g, 0.94 mmole) and Na₂SO₄ (500 mg). After 24h, the reaction contents were concentrated and dried under high vacuum. To a stirred solution of the crude imine in dry EtOH (25 mL) at RT was added NaBH₄ (36 mg, 0.94 mmole). After 24h, the reaction solution was concentrated under vacuum and to the residue was added 1M HCl (5mL) and EtOAc (50 mL). After stirring for 1h, 6M NaOH (1mL) was added and the organic layer was separated, dried (Na₂SO₄) and concentrated. Purification on reverse-phase HPLC (CH₃CN/H₂O, 10-90%) afforded the title compound (0.13 g, 30%) as light yellow solid: ¹H NMR (400 MHz, CDCl₃) δ 9.89

(br s, 1H), 9.15 (m, 1H), 8.90 (m, 1H), 8.57 (d, $J = 9.1$ Hz, 1H), 8.45 (d, $J = 9.1$ Hz, 1H), 8.20 (m, 2H), 7.51 (m, 1H), 7.22 (d, $J = 9.1$ Hz, 1H), 6.88 (d, $J = 7.9$ Hz, 1H), 4.24 (m, 2H), 4.02 (s, 3H), 3.55 (m, 2H), 3.41 (m, 2H), 3.30 (s, 2H). LC-MS (ES) m/e 459 ($M + H$)⁺.

5

Example 11

Preparation of 6-({2-[6-(6-methoxy-[1,5]naphthyridin-4-yl)pyridin-3-yl]ethylamino)methyl)-4*H*-pyrido[3,2-*b*][1,4]oxazin-3-one

According to the procedures of Example 10, except substituting 3-oxo-3,4-dihydro-2*H*-pyrido[3,2-*b*][1,4]oxazine-6-carboxaldehyde (0.14 g, 0.78 mmole), for 3-oxo-3,4-dihydro-2*H*-pyrido[3,2-*b*][1,4]thiazine-6-carboxaldehyde, the title compound (45 mg) was prepared as a light yellow solid: ¹H NMR (400 MHz, CH₃OH-*d*₄) δ 9.12 (m, 2H), 8.75 (m, 1H), 8.53 (m, 3H), 7.57 (d, $J = 9.1$ Hz, 1H), 7.37 (m, 1H), 7.14 (d, $J = 7.6$ Hz, 1H), 4.70 (m, 2H), 4.36 (s, 2H), 4.12 (s, 3H), 3.46 (m, 2H), 3.30 (m, 2H). LC-MS (ES) m/e 443 ($M + H$)⁺.

15

Example 12

Preparation of 6-({2-[5-(6-methoxy-[1,5]naphthyridin-4-yl)pyridin-2-yl]ethylamino)methyl)-4*H*-pyrido[3,2-*b*][1,4]thiazin-3-one

According to the procedures of Example 10, except substituting 2-methoxy-8-(6-methylpyridin-2-yl)[1,5]naphthyridine (0.42 g, 1.67 mmole), for 2-methoxy-8-(5-methylpyridin-3-yl)[1,5]naphthyridine, the title compound (45 mg, 6% for 4 steps) was prepared as a light yellow solid: ¹H NMR (400 MHz, CDCl₃) δ 9.49 (br s, 1H), 9.19 (m, 1H), 8.83 (d, $J = 4.9$ Hz, 1H), 8.47 (d, $J = 9.1$ Hz, 1H), 8.40 (d, $J = 9.1$ Hz, 1H), 7.69 (m, 2H), 7.52 (d, $J = 7.8$ Hz, 1H), 7.22 (d, $J = 9.1$ Hz, 1H), 6.91 (d, $J = 7.9$ Hz, 1H), 4.80 (m, 2H), 3.92 (s, 3H), 3.68 (m, 2H), 3.55 (m, 2H), 3.30 (s, 2H). LC-MS (ES) m/e 459 ($M + H$)⁺.

25

Example 13

Preparation of 6-({2-[4-(6,8-difluoroquinolin-4-yl)phenyl]ethylamino)methyl)-4*H*-pyrido[3,2-*b*][1,4]thiazin-3-one

According to the procedure of Example 1, except substituting {2-[4-(6,8-difluoroquinolin-4-yl)phenyl]ethyl}carbamic acid *tert*-butyl ester (0.13 g, 0.35

30

mmole) for {2-[4-(6-methoxy[1,5]naphthyridin-4-yl)phenyl]ethyl}carbamic acid *tert*-butyl ester, and substituting 2-oxo-2,3-dihydro-1*H*-pyrido[2,3-*b*][1,4]thiazine-7-carboxaldehyde (68 mg, 0.35 mmole) for 3-oxo-3,4-dihydro-2*H*-benzo[1,4]thiazine-6-carboxaldehyde, the title compound (34 mg, 21 %) was prepared as an off-white solid following flash chromatography on silica gel (CHCl₃/MeOH, 9:1, containing 5% NH₄OH): ¹H NMR (400 MHz, CD₃OD) δ 9.22 (d, *J* = 4.5 Hz, 1H), 7.35-8.26 (m, 9H), 4.44 (s, 3H), 3.60 (s, 2H), 3.45 (m, 2H), 3.32 (s, 2H), 3.28 (m, 2H). LC-MS (ES) *m/e* 463 (M + H)⁺.

10

Example 14

Preparation of 6-((2-[4-(8-Fluoro-6-methoxyquinolin-4-yl)phenyl]ethylamino)methyl)-4*H*-pyrido[3,2-*b*][1,4]thiazin-3-one

According to the procedure of Example 1, except substituting {2-[4-(8-fluoro-6-methoxyquinolin-4-yl)phenyl]ethyl}carbamic acid *tert*-butyl ester (0.13 g, 0.35 mmole) for {2-[4-(6-methoxy[1,5]naphthyridin-4-yl)phenyl]ethyl}carbamic acid *tert*-butyl ester, and substituting 2-oxo-2,3-dihydro-1*H*-pyrido[2,3-*b*][1,4]thiazine-7-carboxaldehyde (68 mg, 0.35 mmole) for 3-oxo-3,4-dihydro-2*H*-benzo[1,4]thiazine-6-carboxaldehyde, the title compound (38 mg, 23 %) was prepared as an off-white solid following flash chromatography on silica gel (CHCl₃/MeOH, 9:1, containing 5% NH₄OH): ¹H NMR (400 MHz, CD₃OD) δ 9.22 (d, *J* = 4.5 Hz, 1H), 8.21 (d, *J* = 9.0 Hz, 1H), 8.06 (m, 1H), 7.70-7.85 (m, 6H), 7.13 (d, *J* = 9.0 Hz, 1H), 4.44 (s, 3H), 3.60 (s, 2H), 3.45 (m, 2H), 3.32 (s, 2H), 3.28 (m, 2H). LC-MS (ES) *m/e* 475 (M + H)⁺.

25

Example 15

Preparation of (7-Fluoro-2,3-dihydrobenzo[1,4]dioxin-6-ylmethyl)-(2-[6-(6-methoxy[1,5]naphthyridin-4-yl)-[1,2,4]triazin-3-yl]ethyl)amine.

a) 3-[7-Fluoro-2,3-dihydro-benzo[1,4]dioxin-6-ylmethyl)-amino]propionic acid ethyl ester.

30

To a solution of β-alanine ethyl ester hydrochloride (0.45 g, 2.9 mmol), triethylamine (0.40 mL, 0.29 g, 2.9 mmol) and 7-fluoro-2,3-dihydro-benzo[1,4]dioxine-6-carbaldehyde (0.53 g, 2.9 mmol) in DMF (5.0 mL) was added molecular sieves (4A) at rt. After stirring at rt for 18h, the reaction mixture was

filtered, the solids washed with DMF and the filtrate concentrated under reduced pressure. The residue was purified by vacuum filtration through a pad of silica gel, eluting successively with 1%, 2% and 4% MeOH in CH₂Cl₂ and 90:10:1 CH₂Cl₂ / MeOH / conc. aq. NH₄OH to afford the title compound as a clear oil; yield 0.58 g

5 (71%): LC-MS (ES) 284 (M + H)⁺.

b) 3-[(2,2-Dimethyl-propanoyl)-7-fluoro-2,3-dihydro-benzo[1,4]dioxin-6-ylmethyl)-amino]-propionic acid ethyl ester.

To a solution of 3-[7-fluoro-2,3-dihydrobenzo[1,4]dioxin-6-ylmethyl)-amino]-propionic acid ethyl ester (0.50 g, 1.8 mmol) in MeOH (10 mL) was added di-*tert*-butyl dicarbonate (0.46 g, 2.1 mmol) at rt. After stirring at RT for 18 h, the solvent was evaporated to afford the title compound sufficiently pure [LCMS (ES) m/e 384 (M + H)⁺, 90%]] to use in step (c) without further purification.

15 c) N-(7-Fluoro-2,3-dihydro-benzo[1,4]dioxin-6-ylmethyl)-N-(2-hydrazinocarbonyl-ethyl)-2,2-dimethyl-propionamide.

To a solution of crude 3-[(2,2-dimethyl-propanoyl)-7-fluoro-2,3-dihydro-benzo[1,4]dioxin-6-ylmethyl)-amino]-propionic acid ethyl ester (1.8 mmol maximum) in EtOH (5.0 mL) was added hydrazine hydrate (~55% hydrazine, 0.20 mL, 3.6 mmol). The reaction mixture was heated to reflux for 18 h. The solvent was evaporated and the residue purified by vacuum filtration through a pad of silica gel eluting successively with 2% and 4% MeOH in CH₂Cl₂ and 90:10:1 CH₂Cl₂/MeOH / conc. aq. NH₄OH to afford the title compound; yield 0.31 g (47%, 2-steps): LC-MS (ES) m/e 370 (M + H)⁺.

25

d) N-(7-Fluoro-2,3-dihydrobenzo[1,4]dioxin-6-ylmethyl)-N-{2-[6-(6-methoxy-[1,5]naphthyridin-4-yl)-[1,2,4]triazin-3-ylethyl]-2,2-dimethyl-propionamide.

A solution of N-(7-fluoro-2,3-dihydro-benzo[1,4]dioxin-6-ylmethyl)-N-(2-hydrazinocarbonyl-ethyl)-2,2-dimethylpropionamide (0.30 g, 0.78 mmol) and 2-bromo-1-(6-methoxy[1,5]naphthyridin-4-yl)ethanone (0.10 g, 0.36 mmol) in DMF (5.0 mL) was heated to 120 °C for 3 h. The solvent was removed under reduced pressure and the residue was purified by vacuum filtration through a pad of silica gel eluting successively with 1%, 2% and 4% MeOH in CH₂Cl₂ to afford the title compound as a yellow oil; yield 0.060g (14%): LC-MS (ES) m/e 549 (M + H)⁺.

30

e) (7-Fluoro-2,3-dihydrobenzo[1,4]dioxin-6-ylmethyl)-{2-[6-(6-methoxy-[1,5]naphthyridin-4-yl)-[1,2,4]triazin-3-yl]ethyl}amine.

To a solution of N-(7-fluoro-2,3-dihydro-benzo[1,4]dioxin-6-ylmethyl)-N-{2-
 5 [6-(6-methoxy-[1,5]naphthyridin-4-yl)-[1,2,4]triazin-3-yl-ethyl]-2,2-dimethyl-
 propionamide (0.060 g, 0.11 mmol) in CH₂Cl₂ (10 mL) was added TFA (1 mL). The
 reaction mixture was stirred at rt for 18 h. Volatile materials were removed under
 reduced pressure and the residue was purified by reverse-phase HPLC eluting with
 a gradient of 5-95% CH₃CN / H₂O. Fractions containing only desired product were
 10 concentrated. Trituration of the residue with ether afforded the TFA salt of the title
 compound as a yellow solid; yield 0.016 g (25%): ¹H NMR (MeOH-d₄): δ 9.87
 (s, 1H); 9.00 (d, 1H, J = 4.6 Hz); 8.40 (d, 1H, J = 9.2 Hz); 8.33 (d, 1H, J = 4.6 Hz);
 7.38 (d, 1H, J = 9.1 Hz); 7.09 (d, 1H, J = 7.2 Hz); 6.81 (d, 1H, J = 10.6 Hz); 4.36 (s,
 2H); 4.31 (d, 2H, J = 4.9 Hz); 4.27 (d, 2H, J = 5.5 Hz); 4.07 (s, 3H); 3.79 – 3.50 (m,
 15 4H)

Example 16

Preparation of (2,3-dihydro[1,4]dioxino[2,3-c]pyridin-7-ylmethyl)(2-{5-[6-(methoxy)-1,5-naphthyridin-4-yl]-2-pyridinyl}ethyl)amine

20 (a) 1,1-dimethylethyl (2-{5-[6-(methoxy)-1,5-naphthyridin-4-yl]-2-pyridinyl}ethyl)carbamate

To a stirred solution of 1,1,1-trifluoromethanesulfonic acid 6-methoxy[1,5]naphthyridin-4-yl ester (2.0 g, 8.42 mmole) in dry dioxane (75 mL) at
 25 RT was added bis(pinacolato)diboron (2.14 g, 8.43 mmole), potassium acetate
 (1.91 g, 19.4 mmole), 1,1-bis(diphenylphosphino)ferrocene (0.18 g, 0.32 mmole)
 and [1,1'-bis(diphenylphosphino)ferrocene]dichloropalladium(II) complexed with
 dichloromethane (1:1) (0.26 g, 0.32 mmole). The reaction contents were heated to
 80 °C for 24h under nitrogen gas and then 1,1-bis(diphenylphosphino)ferrocene
 30 (0.18 g, 0.32 mmole), [1,1'-bis(diphenylphosphino)ferrocene]dichloropalladium(II)
 complexed with dichloromethane (1:1) (0.26 g, 0.32 mmole), potassium carbonate
 (2.68 g, 19.44 mmole) and 1,1-dimethylethyl [2-(5-bromo-2-pyridinyl)ethyl]carbamate
 (1.94 g, 6.48 mmole) were added to the reaction pot.
 After 24h of vigorous stirring at 80 °C, the reaction contents were filtered through a

scinter-glass funnel containing a bed of celite (EtOAc). The filtrate was concentrated under vacuum and purified on silica (EtOAc) to afford the title compound (1.52 g, 62 %) as a tan solid: LC-MS (ES) m/e 381 (M + H)⁺.

- 5 b) (2-{5-[6-(methyloxy)-1,5-naphthyridin-4-yl]-2-pyridinyl}ethyl)amine hydrochloride salt

To a stirred solution of 1,1-dimethylethyl (2-{5-[6-(methyloxy)-1,5-naphthyridin-4-yl]-2-pyridinyl}ethyl)carbamate (4.0 mmole) in dry THF (20 mL) at
10 RT was added 4 M HCl in dioxane (10 mL). After 4h, the reaction suspension was concentrated in vacuo and dried under high vacuum to give the title compound (100%) as an off-white solid: LC-MS (ES) m/e 281 (M+H)⁺.

- 15 c) (2,3-dihydro[1,4]dioxino[2,3-c]pyridin-7-ylmethyl)(2-{5-[6-(methyloxy)-1,5-naphthyridin-4-yl]-2-pyridinyl}ethyl)amine

To a stirred solution of (2-{5-[6-(methyloxy)-1,5-naphthyridin-4-yl]-2-pyridinyl}ethyl)amine hydrochloride salt (0.69 mmole) in dry CH₂Cl₂ (25 mL) and dry EtOH (10 mL) at RT was added triethylamine (0.29 mL, 2.07 mmole) and 2,3-dihydro[1,4]dioxino[2,3-c]pyridine-7-carbaldehyde (0.12 g, 0.73 mmole). After 24h,
20 the reaction contents were concentrated and dried under high vacuum. To a stirred solution of the crude imine in dry EtOH (25 mL) at RT was added NaBH₄ (0.03 g, 0.73 mmole). After 24h, Silica gel (5 g) was added to the reaction solution and the suspension was concentrated under vacuum to a dry solid. Purification on silica (CHCl₃/MeOH, 9:1 containing 5% NH₄OH) afforded the title compound (0.50 g,
25 72%) as light yellow solid: ¹H NMR (400 MHz, CD₃OD) δ 9.52 (d, J = 1.8 Hz, 1H), 9.22 (d, J = 5.6 Hz, 1H), 9.02 (d, J = 8.3 Hz, 1H), 8.57 (m, 2H), 8.48 (d, J = 5.6 Hz, 1H), 8.19 (d, J = 9.3 Hz, 1H), 7.79 (s, 1H), 7.68 (d, J = 9.3 Hz, 1H), 4.66 (m, 4H), 4.54 (s, 2H), 4.13 (s, 3H), 3.82 (m, 2H), 3.71 (s, 2H). LC-MS (ES) m/e 430 (M + H)⁺.

30

Example 17Preparation of (2,3-dihydro[1,4]dioxino[2,3-c]pyridin-7-ylmethyl)(2-{6-[6-(methyloxy)-1,5-naphthyridin-4-yl]-3-pyridinyl}ethyl)amine

5 According to the procedure of Example 16, except substituting 1,1-dimethylethyl [2-(6-chloro-3-pyridinyl)ethyl]carbamate (1.0 g, 3.90 mmole) for 1,1-dimethylethyl [2-(5-bromo-2-pyridinyl)ethyl]carbamate, the title compound (0.16 g, 40 % overall yield) was prepared as an off-white solid following flash chromatography on silica gel (CHCl₃/MeOH, 9:1, containing 5% NH₄OH): ¹H NMR (400 MHz, CD₃OD) δ 9.17 (m, 2H), 8.75 (d, *J* = 8.3 Hz, 1H), 8.66 (d, *J* = 8.3 Hz, 1H), 8.49-8.54 (m, 3H), 7.76 (s, 1H), 7.56 (d, *J* = 9.3 Hz, 1H), 4.67 (m, 2H), 4.63 (s, 2H), 4.53 (m, 2H), 4.14 (s, 3H), 3.70 (m, 2H), 3.51 (m, 2H). LC-MS (ES) *m/e* 430 (M + H)⁺.

15

Example 18Preparation of N-(2-{5-[6-(methyloxy)-1,5-naphthyridin-4-yl]-2-pyridinyl}ethyl)-3-oxo-3,4-dihydro-2H-pyrido[3,2-*b*][1,4]thiazine-6-carboxamide

20 To a stirred solution of (2-{5-[6-(methyloxy)-1,5-naphthyridin-4-yl]-2-pyridinyl}ethyl)amine hydrochloride salt (1.08 mmole) in DMF (25 mL) at RT was added diisopropylethylamine (0.75 mL, 4.32 mmole), 3-oxo-3,4-dihydro-2H-pyrido[3,2-*b*][1,4]thiazine-6-carboxylic acid (0.23 g, 1.08 mmole), hydroxybenzotriazole hydrate (0.16 g, 1.19 mmole) and EDC (0.23 g, 1.19 mmole).
25 After 18h, the reaction contents were concentrated and dried under high vacuum. Purification on silica (CHCl₃/MeOH, 9:1 containing 5% NH₄OH) afforded the title compound (0.40 g, 79%) as light yellow solid: ¹H NMR (400 MHz, CD₃OD) δ 9.55 (m, 1H), 9.19 (m, 1H), 9.09 (d, *J* = 8.3 Hz, 1H), 8.53 (d, *J* = 9.2 Hz, 1H), 8.42 (m, 1H), 8.23 (d, *J* = 7.7 Hz, 1H), 7.88 (d, *J* = 8.3 Hz, 1H), 7.61 (m, 2H), 4.5 (s, 3H),
30 4.02 (m, 2H), 3.62 (m, 2H), 3.54 (m, 2H). LC-MS (ES) *m/e* 473 (M + H)⁺.


Example 19Preparation of *N*-(2-{6-[6-(methyloxy)-1,5-naphthyridin-4-yl]-3-pyridinyl}ethyl)-3-oxo-3,4-dihydro-2*H*-pyrido[3,2-*b*][1,4]thiazine-6-carboxamide

- 5 According to the procedure of Example 18, except substituting (2-{6-[6-(methyloxy)-1,5-naphthyridin-4-yl]-3-pyridinyl}ethyl)amine hydrochloride salt (0.89 mmole) for (2-{5-[6-(methyloxy)-1,5-naphthyridin-4-yl]-2-pyridinyl}ethyl)amine hydrochloride salt, the title compound (0.31 g, 75 % yield) was prepared as an off-white solid following flash chromatography on silica gel (CHCl₃/MeOH, 9:1, containing 5% NH₄OH): ¹H
- 10 NMR (400 MHz, CD₃OD) δ 9.05 (m, 2H), 8.61 (m, 2H), 8.46 (d, *J* = 9.1 Hz, 1H), 8.31 (m, 1H), 7.88 (d, *J* = 7.3 Hz, 1H), 7.65 (m, 1H), 7.48 (d, *J* = 9.1 Hz, 1H), 4.03 (s, 3H), 3.87 (m, 2H), 3.79 (m, 2H), 3.24 (m, 2H). LC-MS (ES) *m/e* 473 (M + H)⁺.

What is claimed is:

1. A compound of formula (I):

5



wherein:

one of Z_1 , Z_2 , Z_3 , Z_4 and Z_5 is N, one is CR^{1a} and the remainder are CH , or

10 one or two of Z_1 , Z_2 , Z_3 , Z_4 and Z_5 are independently CR^{1a} and the remainder are CH;

R^1 and R^{1a} are independently hydrogen; hydroxy; (C_{1-6}) alkoxy unsubstituted or substituted by (C_{1-6}) alkoxy, amino, piperidyl, guanidino or amidino any of which is
 15 optionally N-substituted by one or two (C_{1-6}) alkyl, acyl or (C_{1-6}) alkylsulphonyl groups, $CONH_2$, hydroxy, (C_{1-6}) alkylthio, heterocyclylthio, heterocyclyoxy, arylthio, aryloxy, acylthio, acyloxy or (C_{1-6}) alkylsulphonyloxy; (C_{1-6}) alkoxy-substituted (C_{1-6}) alkyl; halogen; (C_{1-6}) alkyl; (C_{1-6}) alkylthio; trifluoromethyl; trifluoromethoxy; nitro; cyano; azido; acyl; acyloxy; acylthio; (C_{1-6}) alkylsulphonyl; (C_{1-6}) alkylsulphoxide;
 20 arylsulphonyl; arylsulphoxide or an amino, piperidyl, guanidino or amidino group optionally N-substituted by one or two (C_{1-6}) alkyl, acyl or (C_{1-6}) alkylsulphonyl groups;

provided that when Z_1 , Z_2 , Z_3 , Z_4 and Z_5 are CR^{1a} or CH, then R^1 is not hydrogen;

W_1 , W_2 , W_3 and W_4 are each independently selected from N or CR^3 ;

each R^3 is independently selected from:

- 5 hydrogen; hydroxy; halogen; trifluoromethyl; trifluoromethoxy; cyano; nitro; azido; acyl; acyloxy; acylthio; amino, mono- and di-(C_{1-6})alkylamino; and substituted and unsubstituted (C_{1-6})alkoxy, (C_{1-6})alkyl, (C_{3-7})cycloalkyl, aminocarbonyl, (C_{1-6})alkylthio, (C_{1-6})alkylsulphonyl, and (C_{1-6})alkylsulphoxide;

- 10 A is $(CRR)_n$;

B is $(CRR)_m$, $C=O$, or SO_2 ;

n is 1 or 2;

m is 1 or 2


provided that when n is 1, m is 2; when n is 2, m is 1; and when B is $C=O$ or SO_2

- 15 then n is 2;

each R is independently selected from

hydrogen; halogen; trifluoromethyl; trifluoromethoxy; cyano; nitro; azido; acyl; acyloxy; acylthio; amino, mono- and di-(C_{1-6})alkylamino; and substituted and
 20 unsubstituted (C_{1-6})alkoxy, (C_{1-6})alkyl, (C_{3-7})cycloalkyl, aminocarbonyl, (C_{1-6})alkylthio, (C_{1-6})alkylsulphonyl, and (C_{1-6})alkylsulphoxide;

R^2 is a substituted or unsubstituted bicyclic carbocyclic or heterocyclic ring system of formula (A):



25

containing up to four heteroatoms in each ring in which

ring (a) is aromatic and ring (b) is aromatic or non-aromatic;

X^1 is C;

X^2 is N, NR^6 , O, $S(O)_x$, CO, CR^4 or CR^4R^5 ;

- 30 X^3 and X^4 are each independently N or C;

Y¹ is a 1 to 2 atom linker group each atom of which is independently selected from N and CR⁴;

Y² is a 2 to 6 atom linker group, each atom of Y² being independently selected from N, NR⁶, O, S(O)_x, CO, CR⁴ and CR⁴R⁵;

5

- each R⁴ and R⁵ is independently selected from: hydrogen; (C₁₋₄)alkylthio; halo; carboxy(C₁₋₄)alkyl; halo(C₁₋₄)alkoxy; halo(C₁₋₄)alkyl; (C₁₋₄)alkyl; (C₂₋₄)alkenyl; (C₁₋₄)alkoxycarbonyl; formyl; (C₁₋₄)alkylcarbonyl; (C₂₋₄)alkenyloxycarbonyl; (C₂₋₄)alkenylcarbonyl; (C₁₋₄)alkylcarbonyloxy; (C₁₋₄)alkoxycarbonyl(C₁₋₄)alkyl;
- 10 hydroxy; hydroxy(C₁₋₄)alkyl; mercapto(C₁₋₄)alkyl; (C₁₋₄)alkoxy; nitro; cyano; carboxy; amino or aminocarbonyl is optionally substituted by (C₁₋₄)alkoxycarbonyl, (C₁₋₄)alkylcarbonyl, (C₂₋₄)alkenyloxycarbonyl, (C₂₋₄)alkenylcarbonyl, (C₁₋₄)alkyl or (C₂₋₄)alkenyl and optionally further substituted by (C₁₋₄)alkyl or (C₂₋₄)alkenyl; (C₂₋₆)alkenyl;
- 15 (C₁₋₄)alkylsulphonyl; (C₂₋₄)alkenylsulphonyl; or aminosulphonyl wherein the amino group is optionally mono- or di-substituted by (C₁₋₄)alkyl or (C₂₋₄)alkenyl; aryl; aryl(C₁₋₄)alkyl; aryl(C₁₋₄)alkoxy; or R⁴ and R⁵ may together represent oxo;

- each R⁶ is independently hydrogen; trifluoromethyl; (C₁₋₄)alkyl unsubstituted or
- 20 substituted by hydroxy, (C₁₋₆)alkoxy, (C₁₋₆)alkylthio, halo or trifluoromethyl; (C₂₋₄)alkenyl; aryl; aryl(C₁₋₄)alkyl; arylcarbonyl; heteroarylcarbonyl; (C₁₋₄)alkoxycarbonyl; (C₁₋₄)alkylcarbonyl; formyl; (C₁₋₆)alkylsulphonyl; or aminocarbonyl wherein the amino group is optionally substituted by (C₁₋₄)alkoxycarbonyl, (C₁₋₄)alkylcarbonyl, (C₂₋₄)alkenyloxycarbonyl,
- 25 (C₂₋₄)alkenylcarbonyl, (C₁₋₄)alkyl or (C₂₋₄)alkenyl and optionally further substituted by (C₁₋₄)alkyl or (C₂₋₄)alkenyl; and
- each x is independently 0, 1, or 2; or a pharmaceutically acceptable salt thereof.

2. A compound according to claim 1 wherein Z_5 is CH or N, Z_3 is CH or CF and Z_1 , Z_2 and Z_4 are each CH, or Z_1 is N, Z_3 is CH or CF and Z_2 , Z_4 and Z_5 are each CH.
- 5 3. A compound according to claim 1 wherein R^1 is methoxy and R^{1a} is H or when Z_3 is CR^{1a} it may be C-F.
4. A compound according to claim 1 wherein:
- a) W_1 - W_4 are independently CR^3 ;
- 10 b) W_1 , W_3 and W_4 are N and W_2 is CR^3 ;
- c) W_2 is N and W_1 , W_3 and W_4 are independently CR^3 ;
- d) W_3 is N and W_1 , W_2 and W_4 are independently CR^3 ; or
- e) W_4 is N and W_1 - W_3 are independently CR^3 .
- 15 5. A compound according to claim 1 wherein R^3 is independently selected from hydrogen, substituted and unsubstituted (C_{1-6}) alkoxy, and NH_2 .
6. A compound according to claim 1 wherein R is independently selected from hydrogen, substituted and unsubstituted (C_{1-6}) alkyl, $CONH_2$, $COOH$, hydroxy,
- 20 halogen, and substituted and unsubstituted (C_{1-6}) alkoxy.
7. A compound according to claim 1 wherein in the heterocyclic ring (A), Y^2 has 3-5 atoms including NR^6 , O or S bonded to X^4 and $NHCO$ bonded via N to X^3 , or O or NH bonded to X^3 .
- 25 8. A compound according to claim 1 wherein R^2 is selected from
- 4*H*-benzo[1,4]thiazin-3-one-6-yl,
- 4*H*-pyrido[3,2-*b*][1,4]thiazin-3-one-6-yl,
- 4*H*-pyrido[3,2-*b*][1,4]oxazin-3-one-6-yl,
- 30 1,2,3,4-tetrahydro-[1,8]naphthyridine-7-yl,
- 1*H*-pyrido[3,2-*b*][1,4]thiazin-2-one-7-yl,

4*H*-benzo[1,4]oxazin-3-one-6-yl, and
6-fluoro-2,3-dihydrobenzo[1,4]dioxine-7-yl.

9. A compound according to claim 1 which is:

- 5 6-({2-[4-(6-Methoxy-[1,5]naphthyridin-4-yl)phenyl]ethylamino)methyl)-4*H*-
benzo[1,4]thiazin-3-one;
 6-({2-[4-(6-Methoxy-[1,5]naphthyridin-4-yl)phenyl]ethylamino)methyl)-4*H*-
pyrido[3,2-*b*][1,4]thiazin-3-one;
- 10 6-({2-[4-(6-Methoxy-[1,5]naphthyridin-4-yl)phenyl]ethylamino)methyl)-4*H*-
pyrido[3,2-*b*][1,4]oxazin-3-one;
 3-Oxo-3,4-dihydro-2*H*-benzo[1,4]thiazine-6-sulfonic acid {2-[4-(6-methoxy-
[1,5]naphthyridin-4-yl)phenyl]ethyl}amide;
 {2-[4-(6-Methoxy-[1,5]naphthyridin-4-yl)phenyl]ethyl} (5,6,7,8-
tetrahydro[1,8]naphthyridin-2-ylmethyl)amine;
- 15 6-({4-(6-Methoxy-[1,5]naphthyridin-4-yl)benzylamino)methyl)-4*H*-
benzo[1,4]thiazin-3-one;
 7-({2-[4-(6-Methoxy-[1,5]naphthyridin-4-yl)phenyl]ethylamino)methyl)-1*H*-
pyrido[3,2-*b*][1,4]thiazin-2-one;
- 20 6-{2-[4-(6-Methoxy-[1,5]naphthyridin-4-yl)benzylamino]ethyl}-4*H*-
benzo[1,4]oxazin-3-one;
 6-{2-[4-(6-Methoxy-[1,5]naphthyridin-4-yl)benzylamino]ethyl}-4*H*-
benzo[1,4]thiazin-3-one;
- (7-Fluoro-2,3-dihydrobenzo[1,4]dioxin-6-ylmethyl){2-[6-(6-
methoxy[1,5]naphthyridin-4-yl)[1,2,4]triazin-3-yl]ethyl}amine;
- 25 6-({2-[4-(6-Methoxyquinolin-4-yl)phenyl]ethylamino)methyl)-4*H*-pyrido[3,2-
b][1,4]oxazin-3-one;
 6-({2-[4-(6,8-difluoroquinolin-4-yl)phenyl]ethylamino)methyl)-4*H*-pyrido[3,2-
b][1,4]thiazin-3-one;
- 30 6-({2-[4-(8-Fluoro-6-methoxyquinolin-4-yl)phenyl]ethylamino)methyl)-4*H*-
pyrido[3,2-*b*][1,4]thiazin-3-one;
 6-({2-[6-(6-methoxy-[1,5]naphthyridin-4-yl)pyridin-3-yl]ethylamino)methyl)-
4*H*-pyrido[3,2-*b*][1,4]thiazin-3-one;
- 35 6-({2-[5-(6-methoxy-[1,5]naphthyridin-4-yl)pyridin-2-yl]ethylamino)methyl)-
4*H*-pyrido[3,2-*b*][1,4]thiazin-3-one;
 6-({2-[6-(6-methoxy-[1,5]naphthyridin-4-yl)pyridin-3-yl]ethylamino)methyl)-
4*H*-pyrido[3,2-*b*][1,4]oxazin-3-one;

N-(2,3-dihydro[1,4]dioxino[2,3-*c*]pyridin-7-ylmethyl)-2-{6-[6-(methyloxy)-1,5-naphthyridin-4-yl]-3-pyridinyl}ethanamine;

N-(2,3-dihydro[1,4]dioxino[2,3-*c*]pyridin-7-ylmethyl)-2-{5-[6-(methyloxy)-1,5-naphthyridin-4-yl]-2-pyridinyl}ethanamine;

5 *N*-(2-{6-[6-(methyloxy)-1,5-naphthyridin-4-yl]-3-pyridinyl}ethyl)-3-oxo-3,4-dihydro-2*H*-pyrido[3,2-*b*][1,4]thiazine-6-carboxamide; and

N-(2-{5-[6-(methyloxy)-1,5-naphthyridin-4-yl]-2-pyridinyl}ethyl)-3-oxo-3,4-dihydro-2*H*-pyrido[3,2-*b*][1,4]thiazine-6-carboxamide;

or a pharmaceutically acceptable salt thereof.

10

10. A pharmaceutical composition comprising a compound according to claim 1 and a pharmaceutically acceptable carrier.

11. A method of treating bacterial infections in mammals which comprises the
15 administration to a mammal in need thereof an effective amount of a compound according to claim 1.